<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Medical interventions for treating anthracycline‐induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer - Cheuk, DKL - 2016 | Cochrane Library</title> <meta content="Medical interventions for treating anthracycline‐induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer - Cheuk, DKL - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008011.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Medical interventions for treating anthracycline‐induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer - Cheuk, DKL - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008011.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008011.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Medical interventions for treating anthracycline‐induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer" name="citation_title"/> <meta content="Daniel KL Cheuk&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="The University of Hong Kong, Queen Mary Hospital" name="citation_author_institution"/> <meta content="cheukkld@hkucc.hku.hk" name="citation_author_email"/> <meta content="Elske Sieswerda" name="citation_author"/> <meta content="Emma Children's Hospital/Academic Medical Center" name="citation_author_institution"/> <meta content="Elvira C van Dalen" name="citation_author"/> <meta content="Emma Children's Hospital/Academic Medical Center" name="citation_author_institution"/> <meta content="Aleida Postma" name="citation_author"/> <meta content="University Medical Center Groningen and University of Groningen, Beatrix Children's Hospital" name="citation_author_institution"/> <meta content="Leontien CM Kremer" name="citation_author"/> <meta content="Emma Children's Hospital/Academic Medical Center" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD008011.pub3" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/08/23" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008011.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008011.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008011.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adult Survivors of Child Adverse Events; Angiotensin‐Converting Enzyme Inhibitors [adverse effects, *therapeutic use]; Anthracyclines [*administration &amp; dosage, adverse effects]; Antibiotics, Antineoplastic [*adverse effects]; Cardiotonic Agents [*therapeutic use]; Enalapril [adverse effects, *therapeutic use]; Heart Failure [chemically induced, *drug therapy, mortality]; Neoplasms [drug therapy]; Phosphocreatine [*therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008011.pub3&amp;doi=10.1002/14651858.CD008011.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008011.pub3&amp;doi=10.1002/14651858.CD008011.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008011.pub3&amp;doi=10.1002/14651858.CD008011.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008011.pub3&amp;doi=10.1002/14651858.CD008011.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008011.pub3&amp;doi=10.1002/14651858.CD008011.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008011.pub3&amp;doi=10.1002/14651858.CD008011.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008011.pub3&amp;doi=10.1002/14651858.CD008011.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008011.pub3&amp;doi=10.1002/14651858.CD008011.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008011.pub3&amp;doi=10.1002/14651858.CD008011.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008011.pub3&amp;doi=10.1002/14651858.CD008011.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008011.pub3&amp;doi=10.1002/14651858.CD008011.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008011.pub3&amp;doi=10.1002/14651858.CD008011.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008011.pub3&amp;doi=10.1002/14651858.CD008011.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008011.pub3&amp;doi=10.1002/14651858.CD008011.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008011.pub3&amp;doi=10.1002/14651858.CD008011.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008011.pub3&amp;doi=10.1002/14651858.CD008011.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008011.pub3&amp;doi=10.1002/14651858.CD008011.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008011.pub3&amp;doi=10.1002/14651858.CD008011.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008011.pub3&amp;doi=10.1002/14651858.CD008011.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008011.pub3&amp;doi=10.1002/14651858.CD008011.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008011.pub3&amp;doi=10.1002/14651858.CD008011.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008011.pub3&amp;doi=10.1002/14651858.CD008011.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008011.pub3&amp;doi=10.1002/14651858.CD008011.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="jxlIh5Me";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008011\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008011\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008011\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008011\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ko","ja","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008011.pub3",title:"Medical interventions for treating anthracycline\\u2010induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer",firstPublishedDate:"Aug 23, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Childhood Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jxlIh5Me&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008011.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008011.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008011.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008011.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008011.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008011.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;アブストラクト&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008011.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008011.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008011.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008011.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2374 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008011.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008011.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008011.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008011.pub3/full#CD008011-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008011.pub3/full#CD008011-sec-0084"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008011.pub3/full#CD008011-sec-0036"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008011.pub3/full#CD008011-sec-0040"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008011.pub3/full#CD008011-sec-0041"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008011.pub3/full#CD008011-sec-0063"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008011.pub3/full#CD008011-sec-0083"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008011.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008011.pub3/appendices#CD008011-sec-0089"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008011.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008011.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/table_n/CD008011StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/table_n/CD008011StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008011.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008011.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008011.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008011.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008011.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008011.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Medical interventions for treating anthracycline‐induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="Joint first authorship with Elske Sieswerda"><a href="/cdsr/doi/10.1002/14651858.CD008011.pub3/information#CD008011-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Daniel KL Cheuk</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008011.pub3/information#CD008011-cr-0003">Elske Sieswerda</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008011.pub3/information#CD008011-cr-0004">Elvira C van Dalen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008011.pub3/information#CD008011-cr-0005">Aleida Postma</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008011.pub3/information#CD008011-cr-0006">Leontien CM Kremer</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/information/en#CD008011-sec-0097">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 23 August 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008011.pub3">https://doi.org/10.1002/14651858.CD008011.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008011-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008011-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008011-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008011-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD008011-abs-0003">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008011-abs-0002">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008011-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008011-abs-0001" lang="en"> <section id="CD008011-sec-0001"> <h3 class="title" id="CD008011-sec-0001">Background</h3> <p>Anthracyclines are frequently used chemotherapeutic agents for childhood cancer that can cause cardiotoxicity during and after treatment. Although several medical interventions in adults with symptomatic or asymptomatic cardiac dysfunction due to other causes are beneficial, it is not known if the same treatments are effective for childhood cancer patients and survivors with anthracycline‐induced cardiotoxicity. This review is an update of a previously published Cochrane review. </p> </section> <section id="CD008011-sec-0002"> <h3 class="title" id="CD008011-sec-0002">Objectives</h3> <p>To compare the effect of medical interventions on anthracycline‐induced cardiotoxicity in childhood cancer patients or survivors with the effect of placebo, other medical interventions, or no treatment. </p> </section> <section id="CD008011-sec-0003"> <h3 class="title" id="CD008011-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library, 2015, Issue 8), MEDLINE/PubMed (1949 to September 2015), and EMBASE/Ovid (1980 to September 2015) for potentially relevant articles. In addition, we searched reference lists of relevant articles, conference proceedings of the International Society for Paediatric Oncology (SIOP), the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the International Conference on Long‐Term Complications of Treatment of Children &amp; Adolescents for Cancer, and the European Symposium on Late Complications from Childhood Cancer (from 2005 to 2015), and ongoing trial databases (the ISRCTN Register, the National Institutes of Health (NIH) Register, and the trials register of the World Health Organization (WHO); all searched in September 2015). </p> </section> <section id="CD008011-sec-0004"> <h3 class="title" id="CD008011-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) or controlled clinical trials (CCTs) comparing the effectiveness of medical interventions to treat anthracycline‐induced cardiotoxicity with either placebo, other medical interventions, or no treatment. </p> </section> <section id="CD008011-sec-0005"> <h3 class="title" id="CD008011-sec-0005">Data collection and analysis</h3> <p>Two review authors independently performed the study selection. One review author performed the data extraction and 'Risk of bias' assessments, which another review author checked. We performed analyses according to the guidelines in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>. </p> </section> <section id="CD008011-sec-0006"> <h3 class="title" id="CD008011-sec-0006">Main results</h3> <p>In the original version of the review we identified two RCTs; in this update we identified no additional studies. One trial (135 participants) compared enalapril with placebo in childhood cancer survivors with asymptomatic anthracycline‐induced cardiac dysfunction. The other trial (68 participants) compared a two‐week treatment of phosphocreatine with a control treatment (vitamin C, adenosine triphosphate, vitamin E, oral coenzyme Q10) in leukaemia patients with anthracycline‐induced cardiotoxicity. Both studies had methodological limitations. </p> <p>The RCT on enalapril showed no statistically significant differences in overall survival, mortality due to heart failure, development of clinical heart failure, and quality of life between treatment and control groups. A post‐hoc analysis showed a decrease (that is improvement) in one measure of cardiac function (left ventricular end‐systolic wall stress (LVESWS): ‐8.62% change) compared with placebo (+1.66% change) in the first year of treatment (P = 0.036), but not afterwards. Participants treated with enalapril had a higher risk of dizziness or hypotension (risk ratio 7.17, 95% confidence interval 1.71 to 30.17) and fatigue (Fisher's exact test, P = 0.013). </p> <p>The RCT on phosphocreatine found no differences in overall survival, mortality due to heart failure, echocardiographic cardiac function, and adverse events between treatment and control groups. </p> </section> <section id="CD008011-sec-0007"> <h3 class="title" id="CD008011-sec-0007">Authors' conclusions</h3> <p>Only one trial evaluated the effect of enalapril in childhood cancer survivors with asymptomatic cardiac dysfunction. Although there is some evidence that enalapril temporarily improves one parameter of cardiac function (LVESWS), it is unclear whether it improves clinical outcomes. Enalapril was associated with a higher risk of dizziness or hypotension and fatigue. Clinicians should weigh the possible benefits with the known side effects of enalapril in childhood cancer survivors with asymptomatic anthracycline‐induced cardiotoxicity. </p> <p>Only one trial evaluated the effect of phosphocreatine in childhood cancer patients with anthracycline‐induced cardiotoxicity. Limited data with a high risk of bias showed no significant difference between phosphocreatine and control treatments on echocardiographic function and clinical outcomes. </p> <p>We did not identify any RCTs or CCTs studying other medical interventions for symptomatic or asymptomatic cardiotoxicity in childhood cancer patients or survivors. </p> <p>High‐quality studies should be performed.</p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008011-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008011-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008011-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008011-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD008011-abs-0007">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008011-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/ru#CD008011-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008011-abs-0013">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008011-abs-0004" lang="en"> <h3>Treatment for cardiac problems caused by anthracycline chemotherapy for childhood cancer </h3> <p>Anthracyclines are anticancer drugs used in the treatment of different types of childhood cancer. An important adverse effect of anthracyclines is damage to the heart, which can lead to asymptomatic (without complaints) or symptomatic (with complaints) cardiac problems during and after cancer treatment. While there are several drugs available to treat other types of cardiac problems in adults, it is not known if these drugs are beneficial in treating cardiac problems caused by anthracyclines in childhood cancer patients and survivors. A physician confronted with a childhood cancer patient or survivor with anthracycline‐induced cardiac problems should be able to make an informed decision on how to treat this patient based on high‐quality evidence about the beneficial and adverse effects of the treatment options. We searched for and summarised studies that evaluated drugs for treating anthracycline‐induced cardiac problems in childhood cancer patients and survivors. </p> <p>We identified two randomised studies evaluating two different drugs in two different types of patients. One of these drugs, an angiotensin‐converting enzyme (ACE) inhibitor (enalapril), had a short‐term beneficial effect on heart function in survivors of childhood cancer with asymptomatic cardiac problems caused by anthracyclines compared with placebo. However, the drug had no significant beneficial effect on other important outcomes and was associated with side effects such as dizziness and fatigue. This study was of reasonable/good quality. The other study was of low quality and found no effect of a short treatment with phosphocreatine in childhood leukaemia patients with symptomatic or asymptomatic cardiac problems compared with a control treatment with vitamin C, adenosine triphosphate, vitamin E, and oral coenzyme Q10. </p> <p>We could make no definitive conclusions about treatment options for anthracycline‐induced cardiac problems in childhood cancer patients and survivors. High‐quality studies are needed to determine if there are drugs that improve heart function in these patients. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008011-sec-0084" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008011-sec-0084"></div> <h3 class="title" id="CD008011-sec-0085">Implications for practice</h3> <section id="CD008011-sec-0085"> <p>We identified one RCT comparing enalapril and placebo in childhood cancer survivors with asymptomatic cardiotoxicity (<a href="./references#CD008011-bbs2-0002" title="GreevyR , LuB , SilberJH , RosenbaumPR . Optimal multivariate matching before randomization. Biostatistics2004;5(2):263‐75. GreevyR , SilberJH , CnaanA , RosenbaumPR . Randomization inference with imperfect compliance in the ACE‐inhibitor after anthracycline randomized trial. Journal of the American Statistical Association2004;99(465):7‐15. SilberJH . Challenges in conducting a pediatric longitudinal prevention study: lessons from the ACE‐inhibitor after anthracycline trial. Progress in Pediatric Cardiology2005;20:65‐70. SilberJH . The role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatric Blood &amp; Cancer2005;44:607‐13. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAHJ , RychikJ , et al. Design and baseline characteristics for the ACE inhibitor after anthracycline (AAA) study of cardiac dysfunction in long‐term pediatric cancer survivors. American Heart Journal2001;142:577‐85. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAJ , RychikJ , et al. Enalapril to prevent cardiac function decline in long‐term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology2004;22(5):820‐8. ">Silber 2004</a>). Although there is some evidence that enalapril temporarily improves one parameter of cardiac function (LVESWS), the current evidence did not show a statistically significant improvement of other parameters of cardiac function nor of clinical outcomes such as overall survival, mortality due to heart failure, occurrence of clinical heart failure, and quality of life. However, 'no evidence of effect' should not be confused with 'evidence of no effect'. The RCT showed that enalapril treatment is associated with a higher risk of dizziness or hypotension and fatigue. Effects of enalapril on (duration of) hospitalisation, change in NYHA stage of heart failure, and costs were not studied. Also, no evidence was available on the effects of enalapril beyond 2.8 years of follow‐up and on treating symptomatic cardiotoxicity. Based on the currently available evidence in childhood cancer survivors with asymptomatic anthracycline‐induced cardiac dysfunction, we are not able to provide appropriate recommendations for clinical practice. Clinicians should weigh the potential benefits of enalapril with the known side effects in childhood cancer survivors with asymptomatic anthracycline‐induced cardiac dysfunction. </p> <p>We identified one RCT comparing phosphocreatine and a control treatment of vitamin C, ATP, vitamin E, and oral coenzyme Q10 in childhood leukaemia patients with symptomatic and asymptomatic cardiotoxicity (<a href="./references#CD008011-bbs2-0001" title="ChenC , ZhouXZ , FanYM , QinLJ , GuoHX , XueHM , et al. Clinical analysis of Sodium phosphocreatine on cardiac toxicity induced by anthracycline antibiotics in acute leukemia children [Unknown original title in Chinese]. Chinese Journal of Cancer Prevention and Treatment2008;15(19):1503‐5, 510. ">Chen 2008</a>). Limited data with a high risk of bias and poor generalisability showed no difference of phosphocreatine compared with a control treatment on overall survival, mortality due to heart failure, echocardiographic function, and adverse events. The effect of the intervention on one marker (hsCRP) was unclear, and effects on occurrence of clinical heart failure, (duration) of hospitalisation, change in NYHA stage of heart failure, and costs were not studied. No evidence was available of the effects of phosphocreatine beyond two weeks of treatment or on the effects of phosphocreatine in survivors of childhood cancer with symptomatic or asymptomatic cardiotoxicity. Based on the currently available evidence, we do not recommend the use of phosphocreatine in clinical practice. </p> <p>We identified no RCTs or CCTs studying other medical interventions for symptomatic or asymptomatic cardiotoxicity in childhood cancer patients or survivors. We can therefore make no conclusions about the effect of other medical interventions in these patients and are unable to provide appropriate recommendations for clinical practice. </p> </section> <h3 class="title" id="CD008011-sec-0086">Implications for research</h3> <section id="CD008011-sec-0086"> <p>One RCT has studied the effect of enalapril in childhood cancer survivors with asymptomatic anthracycline‐induced cardiac dysfunction and found no clear effect on clinical outcomes, possibly due to, among other things, low power of the study (<a href="./references#CD008011-bbs2-0002" title="GreevyR , LuB , SilberJH , RosenbaumPR . Optimal multivariate matching before randomization. Biostatistics2004;5(2):263‐75. GreevyR , SilberJH , CnaanA , RosenbaumPR . Randomization inference with imperfect compliance in the ACE‐inhibitor after anthracycline randomized trial. Journal of the American Statistical Association2004;99(465):7‐15. SilberJH . Challenges in conducting a pediatric longitudinal prevention study: lessons from the ACE‐inhibitor after anthracycline trial. Progress in Pediatric Cardiology2005;20:65‐70. SilberJH . The role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatric Blood &amp; Cancer2005;44:607‐13. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAHJ , RychikJ , et al. Design and baseline characteristics for the ACE inhibitor after anthracycline (AAA) study of cardiac dysfunction in long‐term pediatric cancer survivors. American Heart Journal2001;142:577‐85. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAJ , RychikJ , et al. Enalapril to prevent cardiac function decline in long‐term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology2004;22(5):820‐8. ">Silber 2004</a>). As there is strong evidence that ACE inhibitors are beneficial for asymptomatic cardiac dysfunction in other populations, we urge the scientific community to start high‐quality studies evaluating the effect of enalapril in childhood cancer patients and survivors with symptomatic or asymptomatic anthracycline‐induced cardiotoxicity. These studies should preferably be RCTs, within homogenous populations and with long‐term follow‐up using valid and clinically relevant selection criteria and outcome definitions. Previous treatment with radiotherapy, duration since cancer diagnosis, duration of cardiotoxicity, the age of the patient, the severity of cardiotoxicity, and comorbidity should ideally be taken into account. The number of included participants should be sufficient for the power that is needed for reliable results. In addition, a long‐term follow‐up study of the enalapril trial (<a href="./references#CD008011-bbs2-0002" title="GreevyR , LuB , SilberJH , RosenbaumPR . Optimal multivariate matching before randomization. Biostatistics2004;5(2):263‐75. GreevyR , SilberJH , CnaanA , RosenbaumPR . Randomization inference with imperfect compliance in the ACE‐inhibitor after anthracycline randomized trial. Journal of the American Statistical Association2004;99(465):7‐15. SilberJH . Challenges in conducting a pediatric longitudinal prevention study: lessons from the ACE‐inhibitor after anthracycline trial. Progress in Pediatric Cardiology2005;20:65‐70. SilberJH . The role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatric Blood &amp; Cancer2005;44:607‐13. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAHJ , RychikJ , et al. Design and baseline characteristics for the ACE inhibitor after anthracycline (AAA) study of cardiac dysfunction in long‐term pediatric cancer survivors. American Heart Journal2001;142:577‐85. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAJ , RychikJ , et al. Enalapril to prevent cardiac function decline in long‐term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology2004;22(5):820‐8. ">Silber 2004</a>), evaluating the long‐term effects of enalapril treatment versus placebo, would be very contributory to the current evidence. </p> <p>One low‐quality RCT has studied the effect of phosphocreatine in childhood leukaemia patients with symptomatic or asymptomatic anthracycline‐induced cardiac dysfunction (<a href="./references#CD008011-bbs2-0001" title="ChenC , ZhouXZ , FanYM , QinLJ , GuoHX , XueHM , et al. Clinical analysis of Sodium phosphocreatine on cardiac toxicity induced by anthracycline antibiotics in acute leukemia children [Unknown original title in Chinese]. Chinese Journal of Cancer Prevention and Treatment2008;15(19):1503‐5, 510. ">Chen 2008</a>). Other medical interventions for symptomatic or asymptomatic cardiotoxicity in childhood cancer patients or survivors have not been studied in RCTs or CCTs, even though several potentially beneficial treatment options are available. Evidence on potential treatments for this severe complication is especially needed for symptomatic childhood cancer patients and survivors, therefore, studies with the above‐mentioned criteria should also be started evaluating different treatment options in childhood cancer patients and survivors with symptomatic cardiotoxicity. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008011-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008011-sec-0036"></div> <section id="CD008011-sec-0037"> <h3 class="title" id="CD008011-sec-0037">Description of the condition</h3> <p>Anthracyclines are frequently used chemotherapeutics for childhood cancer that can cause serious cardiac dysfunction (<a href="./references#CD008011-bbs2-0032" title="LefrakEA , PithaJ , RosenheimS , GottliebJA . A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer1973;32(2):302‐14. ">Lefrak 1973</a>; <a href="./references#CD008011-bbs2-0061" title="VanDalenEC , RaphaëlMF , CaronHN , KremerLC . Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD006647.pub4] ">Van Dalen 2014</a>; <a href="./references#CD008011-bbs2-0063" title="VonHoffDD , RozencweigM , LayardM , SlavikM , MuggiaFM . Daunomycin‐induced cardiotoxicity in children and adults. A review of 110 cases. American Journal of Medicine1977;62(2):200‐8. ">Von Hoff 1977</a>). This so‐called anthracycline‐induced cardiotoxicity can develop during, or many years after, treatment and may present clinically, with symptoms of heart failure (<a href="./references#CD008011-bbs2-0041" title="MulrooneyDA , YeazelMW , KawashimaT , MertensAC , MitbyP , StovallM , et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ2009;339:b4606. ">Mulrooney 2009</a>; <a href="./references#CD008011-bbs2-0062" title="Van derPalHJ , vanDalenEC , vanDeldenE , vanDijkIW , KokWE , GeskusRB , et al. High risk of symptomatic cardiac events in childhood cancer survivors. Journal of Clinical Oncology2012;30(13):1429‐37. ">Van der Pal 2012</a>), or subclinically, with abnormalities found only in diagnostic tests (<a href="./references#CD008011-bbs2-0022" title="GanameJ , ClausP , UyttebroeckA , RenardM , D'hoogeJ , BijnensB , et al. Myocardial dysfunction late after low‐dose anthracycline treatment in asymptomatic pediatric patients. Journal of the American Society of Echocardiography2007;20(12):1351‐8. ">Ganame 2007</a>; <a href="./references#CD008011-bbs2-0033" title="LipshultzSE , ColanSD , GelberRD , Perez‐AtaydeAR , SallanSE , SandersSP . Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. The New England Journal of Medicine1991;324(12):808‐15. ">Lipshultz 1991</a>; <a href="./references#CD008011-bbs2-0059" title="VanDalenEC , van DerPalHJ , KokWE , CaronHN , KremerLC . Clinical heart failure in a cohort of children treated with anthracyclines: a long‐term follow‐up study. European Journal of Cancer2006;42(18):3191‐8. ">Van Dalen 2006a</a>). It is estimated that almost 10% of childhood cancer patients treated with anthracycline doses of 300 mg/m² or more will eventually develop symptomatic cardiotoxicity, a condition that is associated with high morbidity and mortality (<a href="./references#CD008011-bbs2-0056" title="SteinherzLJ , SteinherzPG , TanC . Cardiac failure and dysrhythmias 6‐19 years after anthracycline therapy: a series of 15 patients. Medical and Pediatric Oncology1995;24(6):352‐61. ">Steinherz 1995</a>; <a href="./references#CD008011-bbs2-0059" title="VanDalenEC , van DerPalHJ , KokWE , CaronHN , KremerLC . Clinical heart failure in a cohort of children treated with anthracyclines: a long‐term follow‐up study. European Journal of Cancer2006;42(18):3191‐8. ">Van Dalen 2006a</a>). Asymptomatic signs of cardiotoxicity are found in up to 57% of survivors of childhood cancer and are often progressive over time, but the long‐term prognosis of these abnormalities is not known (<a href="./references#CD008011-bbs2-0031" title="KremerLC , van DerPalHJ , OffringaM , vanDalenEC , VoutePA . Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Annals of Oncology2002;13(6):819‐29. ">Kremer 2002</a>; <a href="./references#CD008011-bbs2-0035" title="LipshultzSE , LipsitzSR , SallanSE , DaltonVM , MoneSM , GelberRD , et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. Journal of Clinical Oncology2005;23(12):2629‐36. ">Lipshultz 2005a</a>; <a href="./references#CD008011-bbs2-0054" title="SorensenK , LevittGA , BullC , DorupI , SullivanID . Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer2003;97(8):1991‐8. ">Sorensen 2003</a>). In the general adult population, individuals with asymptomatic cardiac dysfunction are at increased risk of developing symptomatic heart failure and death (<a href="./references#CD008011-bbs2-0065" title="WangTJ , EvansJC , BenjaminEJ , LevyD , LeRoyEC , VasanRS . Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation2003;108(8):977‐82. ">Wang 2003</a>). These findings raise the concern that children and young adults with asymptomatic cardiac dysfunction caused by anthracyclines are also at risk of progression to symptomatic heart failure in the long term. </p> </section> <section id="CD008011-sec-0038"> <h3 class="title" id="CD008011-sec-0038">Description of the intervention</h3> <p>Several cardiovascular drugs have been studied in people with cardiac dysfunction due to other causes. Studies in adults with symptomatic as well as asymptomatic heart failure due to causes other than anthracyclines have shown that treatment of an average duration of three years with angiotensin‐converting enzyme (ACE) inhibitors reduces long‐term morbidity and mortality, regardless of the aetiology of heart failure (<a href="./references#CD008011-bbs2-0011" title="AbdullaJ , PogueJ , AbildstromSZ , KoberL , ChristensenE , PfefferMA , et al. Effect of angiotensin‐converting enzyme inhibition on functional class in patients with left ventricular systolic dysfunction ‐ a meta‐analysis. European Journal of Heart Failure2006;8(1):90‐6. ">Abdulla 2006</a>; <a href="./references#CD008011-bbs2-0023" title="GargR , YusufS . Overview of randomized trials of angiotensin‐converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA1995;273(18):1450‐6. ">Garg 1995</a>; <a href="./references#CD008011-bbs2-0029" title="JongP , YusufS , RousseauMF , AhnSA , BangdiwalaSI . Effect of enalapril on 12‐year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow‐up study. The Lancet2003;361(9372):1843‐8. ">Jong 2003</a>; <a href="./references#CD008011-bbs2-0052" title="Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. The New England Journal of Medicine1991;325(5):293‐302. ">SOLVD 1991</a>; <a href="./references#CD008011-bbs2-0053" title="Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. The New England Journal of Medicine1992;327(10):685‐91. ">SOLVD 1992</a>). The Studies of Left Ventricular Dysfunction (SOLVD) also showed an improvement in quality of life in symptomatic participants and no negative effect in quality of life in asymptomatic participants (<a href="./references#CD008011-bbs2-0048" title="RogersWJ , JohnstoneDE , YusufS , WeinerDH , GallagherP , BittnerVA , et al. Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: the Studies of Left Ventricular Dysfunction. Journal of the American College of Cardiology1994;23(2):393‐400. ">Rogers 1994</a>; <a href="./references#CD008011-bbs2-0052" title="Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. The New England Journal of Medicine1991;325(5):293‐302. ">SOLVD 1991</a>; <a href="./references#CD008011-bbs2-0053" title="Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. The New England Journal of Medicine1992;327(10):685‐91. ">SOLVD 1992</a>). A cost‐effectiveness study was performed in symptomatic SOLVD patients and showed survival benefit as well as cost savings (<a href="./references#CD008011-bbs2-0024" title="GlickH , CookJ , KinosianB , PittB , BourassaMG , PouleurH , et al. Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial. Journal of Cardiac Failure1995;1(5):371‐80. ">Glick 1995</a>). Treatment with beta‐blocking agents in addition to an ACE inhibitors improves the mortality outcome in people with symptomatic cardiac failure (<a href="./references#CD008011-bbs2-0016" title="The Cardiac Insufficiency Bisoprolol Study II (CIBIS‐II): a randomised trial. The Lancet1999;353(9146):9‐13. ">CIBIS‐II 1999</a>; <a href="./references#CD008011-bbs2-0021" title="FoodyJM , FarrellMH , KrumholzHM . Beta‐blocker therapy in heart failure: scientific review. JAMA2002;287(7):883‐9. ">Foody 2002</a>; <a href="./references#CD008011-bbs2-0044" title="PackerM , BristowMR , CohnJN , ColucciWS , FowlerMB , GilbertEM , et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. The New England Journal of Medicine1996;334(21):1349‐55. ">Packer 1996a</a>; <a href="./references#CD008011-bbs2-0045" title="PackerM , ColucciWS , Sackner‐BernsteinJD , LiangCS , GoldscherDA , FreemanI , et al. Double‐blind, placebo‐controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation1996;94(11):2793‐9. ">Packer 1996b</a>; <a href="./references#CD008011-bbs2-0064" title="WaagsteinF , BristowMR , SwedbergK , CameriniF , FowlerMB , SilverMA , et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. The Lancet1993;342(8885):1441‐6. ">Waagstein 1993</a>), and improves cardiac function in people with asymptomatic heart failure (<a href="./references#CD008011-bbs2-0019" title="ColucciWS , KoliasTJ , AdamsKF , ArmstrongWF , GhaliJK , GottliebSS , et al. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol‐XL (REVERT) trial. Circulation2007;116(1):49‐56. ">Colucci 2007</a>; <a href="./references#CD008011-bbs2-0020" title="ExnerDV , DriesDL , WaclawiwMA , SheltonB , DomanskiMJ . Beta‐adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. Journal of the American College of Cardiology1999;33(4):916‐23. ">Exner 1999</a>). Other medical interventions may also potentially improve the prognosis of people with symptomatic or asymptomatic heart failure, such as angiotensin receptor blockers (<a href="./references#CD008011-bbs2-0025" title="GrangerCB , McMurrayJJ , YusufS , HeldP , MichelsonEL , OlofssonB , et al. Effects of candesartan in patients with chronic heart failure and reduced left‐ventricular systolic function intolerant to angiotensin‐converting‐enzyme inhibitors: the CHARM‐Alternative trial. The Lancet2003;362(9386):772‐6. ">Granger 2003</a> and <a href="./references#CD008011-bbs2-0037" title="MaggioniAP , AnandI , GottliebSO , LatiniR , TognoniG , CohnJN . Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin‐converting enzyme inhibitors. Journal of the American College of Cardiology2002;40(8):1414‐21. ">Maggioni 2002</a>), or combinations of heart failure medications, such as angiotensin receptor blockers, ACE inhibitors, and beta‐blockers (<a href="./references#CD008011-bbs2-0018" title="CohnJN , TognoniG . A randomized trial of the angiotensin‐receptor blocker valsartan in chronic heart failure. The New England Journal of Medicine2001;345(23):1667‐75. ">Cohn 2001</a>; <a href="./references#CD008011-bbs2-0038" title="McMurrayJJ , OstergrenJ , SwedbergK , GrangerCB , HeldP , MichelsonEL , et al. Effects of candesartan in patients with chronic heart failure and reduced left‐ventricular systolic function taking angiotensin‐converting‐enzyme inhibitors: the CHARM‐Added trial. The Lancet2003;362(9386):767‐71. ">McMurray 2003</a>).  </p> </section> <section id="CD008011-sec-0039"> <h3 class="title" id="CD008011-sec-0039">Why it is important to do this review</h3> <p>Many collaborative groups have advocated screening for cardiac dysfunction in childhood cancer patients and survivors (<a href="./references#CD008011-bbs2-0012" title="ArmenianSH , GelehrterSK , VaseT , VenkatramaniR , LandierW , WilsonKD , et al. Screening for cardiac dysfunction in anthracycline‐exposed childhood cancer survivors. Clinical Cancer Research2014;20(24):6314‐23. ">Armenian 2014</a>; <a href="./references#CD008011-bbs2-0013" title="ArmenianSH , HudsonMM , MulderRL , ChenMH , ConstineLS , DwyerM , et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. The Lancet Oncology2015;16(3):e123‐36. ">Armenian 2015</a>; <a href="./references#CD008011-bbs2-0017" title="Children's Oncology Group. Long‐term follow‐up guidelines for survivors of childhood, adolescent and young adult cancers, version 3.0. Arcadia, CA.2006. Available at: www.survivorshipguidelines.org. ">COG 2006</a>; <a href="./references#CD008011-bbs2-0049" title="SieswerdaE , PostmaA , vanDalenEC , van derPalHJ , TissingWJ , RammelooLA , et al. The Dutch Childhood Oncology Group guideline for follow‐up of asymptomatic cardiac dysfunction in childhood cancer survivors. Annals of Oncology2012;23(8):2191‐8. ">Sieswerda 2012</a>; <a href="./references#CD008011-bbs2-0050" title="Scottish Intercollegiate Guideline Network (SIGN). Long‐term follow up care of survivors of childhood cancer. 2013. SIGN publication no. 132: available at: http://www.sign.ac.uk/pdf/sign132.pdf. Accessed on 8 August 2016.. ">SIGN 2013</a>; <a href="./references#CD008011-bbs2-0051" title="SkinnerR , WallaceWH , LevittG . Therapy based long term follow up: A practice statement (second edition). United Kingdom Children's Cancer Study Group, Late Effects Group 2005. Available at: http://www.uhb.nhs.uk/Downloads/pdf/CancerPbTherapyBasedLongTermFollowUp.pdf. Accessed on 8 August 2016. ">Skinner 2005</a>; <a href="./references#CD008011-bbs2-0055" title="SteinherzLJ , GrahamT , HurwitzR , SondheimerHM , SchwartzRG , ShafferEM , et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the cardiology committee of the Children's Cancer Study Group. Pediatrics1992;89:942‐9. ">Steinherz 1992</a>). However, for appropriate screening for a disease, an effective treatment should be available (<a href="./references#CD008011-bbs2-0066" title="WilsonJMG , JungnerG . Principles and practice of screening for disease. WHO Chronicle1968;22(11):473. ">Wilson 1968</a>). In addition, physicians who are confronted with childhood cancer patients and survivors with cardiac dysfunction should be able to make a well‐informed decision regarding the risks and benefits of treatment options. The optimal treatment for people with anthracycline‐induced cardiotoxicity, and how to decrease morbidity and mortality, are currently unclear (<a href="./references#CD008011-bbs2-0034" title="LipshultzSE , LipsitzSR , SallanSE , SimbreVC , ShaikhSL , MoneSM , et al. Long‐term enalapril therapy for left ventricular dysfunction in doxorubicin‐treated survivors of childhood cancer. Journal of Clinical Oncology2002;20(23):4517‐22. ">Lipshultz 2002</a>; <a href="./references#CD008011-bbs2-0002" title="GreevyR , LuB , SilberJH , RosenbaumPR . Optimal multivariate matching before randomization. Biostatistics2004;5(2):263‐75. GreevyR , SilberJH , CnaanA , RosenbaumPR . Randomization inference with imperfect compliance in the ACE‐inhibitor after anthracycline randomized trial. Journal of the American Statistical Association2004;99(465):7‐15. SilberJH . Challenges in conducting a pediatric longitudinal prevention study: lessons from the ACE‐inhibitor after anthracycline trial. Progress in Pediatric Cardiology2005;20:65‐70. SilberJH . The role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatric Blood &amp; Cancer2005;44:607‐13. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAHJ , RychikJ , et al. Design and baseline characteristics for the ACE inhibitor after anthracycline (AAA) study of cardiac dysfunction in long‐term pediatric cancer survivors. American Heart Journal2001;142:577‐85. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAJ , RychikJ , et al. Enalapril to prevent cardiac function decline in long‐term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology2004;22(5):820‐8. ">Silber 2004</a>; <a href="./references#CD008011-bbs2-0058" title="VanDalenEC , van DerPalHJ , van DenBosC , CaronHN , KremerLC . Treatment for asymptomatic anthracycline‐induced cardiac dysfunction in childhood cancer survivors: the need for evidence. Journal of Clinical Oncology2003;21(17):3377‐8. ">Van Dalen 2003</a>). Although medical interventions in populations with symptomatic and asymptomatic heart failure due to causes other than anthracyclines are beneficial, we cannot assume that the efficacy of this treatment is similar in childhood cancer patients and survivors (<a href="./references#CD008011-bbs2-0030" title="KayJD , ColanSD , GrahamTPJr . Congestive heart failure in pediatric patients. American Heart Journal2001;142(5):923‐8. ">Kay 2001</a>; <a href="./references#CD008011-bbs2-0005" title="ShaddyRE , BoucekMM , HsuDT , BoucekRJ , CanterCE , MahonyL , et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA2007;298(10):1171‐9. ShaddyRE , CurtinEL , SowerB , TaniLY , BurrJ , LaSalleB , et al. The pediatric randomized carvedilol trial in children with heart failure: rationale and design. American Heart Journal2002;144(3):383‐9. ">Shaddy 2007</a>). The different aetiology of the cardiac dysfunction, as well as the different age distribution, make it necessary to study the benefits and risks of treatment of symptomatic and asymptomatic anthracycline‐induced cardiotoxicity in this specific population. Treatment of people with anthracycline‐induced cardiotoxicity should ideally decrease morbidity and mortality, improve cardiac function, reverse disease progression, and improve quality of life. </p> <p>This is an update of the first systematic review, <a href="./references#CD008011-bbs2-0068" title="SieswerdaE , vanDalenEC , PostmaA , CheukDKL , CaronHN , KremerLCM . Medical interventions for treating anthracycline‐induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. Cochrane Database of Systematic Reviews2011, Issue 9. [DOI: 10.1002/14651858.CD008011.pub2] ">Sieswerda 2011</a>, evaluating the current available evidence on medical interventions in both symptomatic and asymptomatic anthracycline‐induced cardiotoxicity during and after treatment for childhood cancer. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008011-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008011-sec-0040"></div> <p>To compare the effect of medical interventions on anthracycline‐induced cardiotoxicity in childhood cancer patients or survivors with the effect of placebo, other medical interventions, or no treatment.   </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008011-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008011-sec-0041"></div> <section id="CD008011-sec-0042"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008011-sec-0043"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) and controlled clinical trials (CCTs) (as defined by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008011-bbs2-0026" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org. ">Higgins 2008</a>)), including non‐inferiority and cross‐over trials, comparing a medical intervention for treating anthracycline‐induced cardiotoxicity with either placebo, other medical intervention(s), or no treatment. </p> </section> <section id="CD008011-sec-0044"> <h4 class="title">Types of participants</h4> <p>Patients and survivors (previously) diagnosed with any type of childhood cancer (defined as a diagnosis of cancer at age 18 years or younger) and with symptomatic or asymptomatic anthracycline‐induced cardiotoxicity. RCTs or CCTs including both children and adults were only eligible for inclusion in this review if the majority of participants were 18 years or younger at cancer diagnosis. Anthracycline‐induced cardiotoxicity, as defined by the authors of the original study, could be diagnosed both during and after anthracycline treatment for childhood cancer. Due to the low number of patients expected, we did not exclude patients who also had been treated with mediastinal radiotherapy. </p> </section> <section id="CD008011-sec-0045"> <h4 class="title">Types of interventions</h4> <p>Medical (that is drug) interventions given with the intention to change the course of anthracycline‐induced symptomatic or asymptomatic cardiotoxicity. We excluded surgical interventions such as heart transplantation. </p> </section> <section id="CD008011-sec-0046"> <h4 class="title">Types of outcome measures</h4> <section id="CD008011-sec-0047"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD008011-list-0001"> <li> <p>Overall survival.</p> </li> <li> <p>Mortality due to heart failure.</p> </li> <li> <p>Development of clinical heart failure as defined by authors.</p> </li> <li> <p>Occurrence of adverse events and tolerability as defined by authors.</p> </li> </ol> </p> </section> <section id="CD008011-sec-0048"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD008011-list-0002"> <li> <p>Change in cardiac function measured by different diagnostic tests as defined by authors.</p> </li> <li> <p>(Duration of) hospitalisation for heart failure.</p> </li> <li> <p>Change in NYHA (New York Heart Association) stage of heart failure (<a href="./references#CD008011-bbs2-0043" title="The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th Edition. Boston: Little, Brown &amp; Co, 1994. ">NYHA 1994</a>). </p> </li> <li> <p>Change in quality of life as defined by authors.</p> </li> <li> <p>Costs as defined by authors.</p> </li> </ol> </p> <p>Outcomes may have been assessed at any time during follow‐up.</p> </section> </section> </section> <section id="CD008011-sec-0049"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD008011-sec-0050"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library, 2015, Issue 8), MEDLINE/PubMed (1949 to 25 September 2015), and EMBASE/Ovid (1980 to 25 September 2015) for potentially relevant articles. </p> <p>The search strategies for CENTRAL, MEDLINE/PubMed, and EMBASE/Ovid are shown in <a href="./appendices#CD008011-sec-0090">Appendix 1</a>, <a href="./appendices#CD008011-sec-0091">Appendix 2</a>, and <a href="./appendices#CD008011-sec-0092">Appendix 3</a>. We used the highly sensitive search strategy for identifying reports of RCTs and CCTs (sensitivity‐maximizing version) as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008011-bbs2-0026" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org. ">Higgins 2008</a>). </p> <p>We scanned the ISRCTN Register (<a href="http://www.isrctn.com" target="_blank">www.isrctn.com</a>), the National Institutes of Health (NIH) Register (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>), and the trials register of the World Health Organization (WHO) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) on 29 September 2015. The search keywords are shown in <a href="./appendices#CD008011-sec-0093">Appendix 4</a>. </p> <p>There were no language restrictions.</p> </section> <section id="CD008011-sec-0051"> <h4 class="title">Searching other resources</h4> <p>We located information about trials not registered in CENTRAL, MEDLINE/PubMed, or EMBASE/Ovid, either published or unpublished, by searching the reference lists of relevant articles and review articles. In addition, we handsearched conference proceedings of the International Society for Paediatric Oncology (SIOP), the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the International Conference on Long‐Term Complications of Treatment of Children &amp; Adolescents for Cancer, and the European Symposium on Late Complications from Childhood Cancer from 2005 up to and including 2015. Again, there were no language restrictions. The search keywords are shown in <a href="./appendices#CD008011-sec-0094">Appendix 5</a>. </p> </section> </section> <section id="CD008011-sec-0052"> <h3 class="title" id="CD008011-sec-0052">Data collection and analysis</h3> <section id="CD008011-sec-0053"> <h4 class="title">Selection of studies</h4> <p>After employing the search strategy described above, two review authors independently identified studies meeting the criteria for this review. We obtained in full any study which seemed to meet the inclusion criteria on the grounds of the title, abstract, or both for closer inspection. The review authors included or excluded studies for this review based on full‐text assessment. Two studies selected for full‐text evaluation were not in a language the authors were familiar with; for these, we contacted Cochrane collaborators from Russia and China, who individually determined if the studies were eligible. We recorded the reasons for exclusion of any study considered for the review. Discrepancies in the selection process were resolved between authors by consensus, or in case of doubt, by consulting a third‐party arbitrator. </p> <p>One review author performed the search of reference lists of relevant articles and review articles, as well as the search within the conference proceedings. </p> <p>We have constructed a flow diagram.</p> </section> <section id="CD008011-sec-0054"> <h4 class="title">Data extraction and management</h4> <p>One review author performed data extraction using standardised forms, which a second review author checked. For the study published in Chinese, this was done by a review author from China based on full text and checked by another review author based on the abstract only. We abstracted information on the following items: </p> <p> <ol id="CD008011-list-0003"> <li> <p>study design;</p> </li> <li> <p>'Risk of bias' items;</p> </li> <li> <p>number of study participants;</p> </li> <li> <p>participants, including:</p> <ol id="CD008011-list-0004"> <li> <p>age at diagnosis;</p> </li> <li> <p>age at study entry;</p> </li> <li> <p>sex;</p> </li> <li> <p>time since diagnosis;</p> </li> <li> <p>study performed during cancer treatment or in survivors;</p> </li> <li> <p>in case of survivors, time since end of cancer treatment;</p> </li> <li> <p>prior anthracycline treatment, including:</p> <ol id="CD008011-list-0005"> <li> <p>type of anthracycline;</p> </li> <li> <p>cumulative anthracycline dose;</p> </li> </ol> </li> <li> <p>other previous treatment, including:</p> <ol id="CD008011-list-0006"> <li> <p>chemotherapy;</p> </li> <li> <p>cardioprotective interventions;</p> </li> <li> <p>radiotherapy on heart region;</p> </li> </ol> </li> <li> <p>comorbidities, including:</p> <ol id="CD008011-list-0007"> <li> <p>cardiovascular disease (specification disease, cause and duration of disease before start of intervention); </p> </li> <li> <p>other (specification disease, cause and duration of disease before start of intervention);</p> </li> </ol> </li> <li> <p>other treatment, including:</p> <ol id="CD008011-list-0008"> <li> <p>other cardiovascular medication (agent, dose, frequency, mode of administration, and duration); </p> </li> <li> <p>other medication (agent, dose, frequency, mode of administration, and duration);</p> </li> <li> <p>cardiovascular surgery (location and procedure);</p> </li> </ol> </li> </ol> </li> <li> <p>interventions, including:</p> <ol id="CD008011-list-0009"> <li> <p>type of medical intervention (substance name, brand name);</p> </li> <li> <p>dose and frequency of medical intervention;</p> </li> <li> <p>mode of administration (oral, intravenous, etc.);</p> </li> <li> <p>duration of medical intervention;</p> </li> <li> <p>duration between diagnosis of anthracycline‐induced cardiotoxicity and start of medical intervention; </p> </li> </ol> </li> <li> <p>outcome measures, including:</p> <ol id="CD008011-list-0010"> <li> <p>outcome definition;</p> </li> <li> <p>timing of outcome measurement;</p> </li> </ol> </li> <li> <p>length of follow‐up.</p> </li> </ol> </p> <p>In cases of disagreement, we re‐examined the abstracts and articles and discussed the topic until consensus was achieved. No third‐party arbitration was needed. </p> </section> <section id="CD008011-sec-0055"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>One review author assessed the risk of bias using a standardised form, which was checked by another review author. The study published in Chinese was assessed by a review author from China based on full text and checked by another review author based on the (English) abstract only. We evaluated the studies according to the following criteria: generation of allocation sequence, concealment of treatment allocation, blinding of the study participants, blinding of personnel, blinding of outcome assessors, completeness of follow‐up, intention‐to‐treat (ITT) analysis, selective outcome reporting, and other sources of bias. We determined the items blinding of outcome assessors, completeness of follow‐up, and ITT analysis for all reported study outcomes. Only for overall survival, we regarded blinding of the outcome assessor not relevant. For all 'Risk of bias' items, we used definitions based on the module of Cochrane Childhood Cancer at the time our protocol was published (<a href="./references#CD008011-bbs2-0040" title="KremerLCM , vanDalenEC , MoherD , Caron HN. Childhood Cancer Group. About the Cochrane Collaboration (Cochrane Review Groups CRGs) 2008, Issue 4. Art. No.: CHILDCA. ">Module CCG</a>), and on the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008011-bbs2-0026" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org. ">Higgins 2008</a>) (see additional <a href="#CD008011-tbl-0001">Table 1</a>). We resolved discrepancies between authors by consensus. In case of doubt, we consulted a third‐party arbitrator. </p> <div class="table" id="CD008011-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Criteria list for the assessment of risk of bias of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Item ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Description</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Implementation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b><i>Selection bias</i> </b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>a</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Was the allocation sequence adequately generated?</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate when a random (and therefore unpredictable) sequence was used to allocate the intervention to the participants </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>b</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Was allocation adequately concealed?</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate when the upcoming allocations of participants were masked from those involved in enrolment into the trial </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b><i>Performance bias</i> </b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>c</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Was knowledge of the allocated intervention by participants adequately prevented during the study?</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate when the participants were unaware of the intervention they received</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>d</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Was knowledge of the allocated intervention by personnel adequately prevented during the study?</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate when the personnel involved in the care of the participants were unaware of the intervention a participant received </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b><i>Detection bias (for each outcome separately)</i> </b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>e</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Was knowledge of the allocated intervention by the outcome assessor adequately prevented during the study?</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate when the outcome assessor was unaware of the intervention a participant received</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b><i>Attrition bias (for each outcome separately)</i> </b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>f</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Was the follow‐up of the outcome complete?</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complete when the outcome was assessed in at least 80% of the study cohort</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>g</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Was an intention‐to‐treat‐analysis performed?</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate when all participants were analysed in the treatment group to which they were randomised, regardless of whether or not they received the allocated intervention </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b><i>Reporting bias</i> </b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>h</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Are reports of the study free of the suggestion of selective outcome reporting?</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate when a study protocol was available that prespecified study outcomes and analyses, which were all reported in the final study report </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b><i>Other sources of bias</i> </b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>i</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Was the study apparently free of other problems that could put it at a high risk of bias?</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate when there were no other important personal concerns about bias not addressed in the other domains in the tool </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>All items were scored yes, no, or unclear.</p> </div> </div> </section> <section id="CD008011-sec-0056"> <h4 class="title">Measures of treatment effect</h4> <p>We related dichotomous outcomes to risk using the risk ratio (RR) and presented all results with the corresponding 95% confidence interval (CI). When only one study was available and there were no events in one of the treatment groups, it was not appropriate to calculate the RR, its 95% CI, and the corresponding P value. For these outcomes, we calculated the Fisher's exact P value instead, using PASW Statistics (SPSS) for Windows version 18 (SPSS Inc., Chicago, IL, USA). We planned to analyse continuous outcomes using the mean difference (MD). However, this was not possible since no standard deviation (SD) of change in the continuous outcomes was provided by the included studies. For the assessment of survival, we planned to use Parmar's method if hazard ratios had not been explicitly presented in the study (<a href="./references#CD008011-bbs2-0046" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17:2815‐34. ">Parmar 1998</a>). However, this was not applicable, since we could not pool the included studies. </p> </section> <section id="CD008011-sec-0057"> <h4 class="title">Dealing with missing data</h4> <p>When information relevant to study selection was missing, we attempted to contact the authors in order to obtain the missing data. </p> <p>We extracted data by allocated intervention, irrespective of compliance with the allocated intervention, in order to allow an ITT analysis. If this was not possible, we stated this and performed an as‐treated analysis. </p> </section> <section id="CD008011-sec-0058"> <h4 class="title">Assessment of heterogeneity</h4> <p>Assessing heterogeneity was not applicable, since we did not pool the included studies.</p> </section> <section id="CD008011-sec-0059"> <h4 class="title">Assessment of reporting biases</h4> <p>We were not able to construct a funnel plot to evaluate the existence of publication bias graphically (<a href="./references#CD008011-bbs2-0026" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org. ">Higgins 2008</a>), since we included only two trials in this review and pooling of results was not possible. As a rule of thumb, tests for funnel plot asymmetry should be used only when there are at least 10 studies included in the meta‐analysis. When there are fewer studies, the power of the tests is too low to distinguish chance from real asymmetry (<a href="./references#CD008011-bbs2-0026" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org. ">Higgins 2008</a>). </p> </section> <section id="CD008011-sec-0060"> <h4 class="title">Data synthesis</h4> <p>We entered the data into RevMan 5.3 (<a href="./references#CD008011-bbs2-0047" title="The Nordic Cochrane Centre. The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre. The Cochrane Collaboration, 2014. ">RevMan 2014</a>), and analysed according to the guidelines of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008011-bbs2-0026" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org. ">Higgins 2008</a>). We used a random‐effects model for the estimation of treatment effects throughout the review. </p> <p>We included outcome measures in this systematic review only if it was the intention of the study authors to perform the necessary assessments in all randomised participants (that is not optional or only performed in some centres). When less than 50% of the participants in a study had an acceptable follow‐up for a particular outcome measure, due to the associated high risk of attrition bias we did not report the results of this outcome measure. </p> <p>We did not perform a pooled analysis since the included trials were not comparable with regard to important study characteristics, that is age, sex, cardiac dysfunction, treatment used, outcome definitions, and length of follow‐up. We therefore summarised the results descriptively. </p> <p>We planned to analyse data separately for clinical heart failure alone versus no clinical heart failure and for clinical and subclinical cardiotoxicity combined versus normal heart function. However, this was not applicable, since pooling was not possible and the study that included both participants with clinical and subclinical heart failure did not provide enough information to allow for such an analysis. </p> </section> <section id="CD008011-sec-0061"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We hypothesised that treatment with mediastinal radiotherapy could cause other cardiac pathology, such as heart valve problems, and that it is therefore possible that treatment effects would differ between patients treated with and without mediastinal radiotherapy. However, we were not able to investigate this type of heterogeneity by performing a subgroup analysis with regard to previous mediastinal radiotherapy because pooling was not possible and because the individual studies did not provide outcomes separately for participants treated with and without previous radiotherapy. </p> </section> <section id="CD008011-sec-0062"> <h4 class="title">Sensitivity analysis</h4> <p>Since we could not pool results, performing a sensitivity analysis using the 'Risk of bias' criteria was not applicable. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008011-sec-0063" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008011-sec-0063"></div> <section id="CD008011-sec-0064"> <h3 class="title">Description of studies</h3> <section id="CD008011-sec-0065"> <h4 class="title">Results of the search</h4> <p>Our original searches in the electronic databases CENTRAL, MEDLINE/PubMed, and EMBASE/Ovid identified 1429 titles with or without an abstract. In the update search of these electronic databases, we identified an additional 480 titles (442 records after removal of duplicates) (<a href="#CD008011-fig-0001">Figure 1</a>), of which we selected eight references reporting on five studies for full‐text assessment. No additional reference in the update search was selected for full‐text assessment. We did not include the remaining 1863 papers because they were not RCTs or CCTs, were laboratory studies, animal studies, did not include children with cancer or survivors of childhood cancer, or were preventive intervention studies of people without signs of cardiotoxicity. While examining the reference lists of relevant papers, we found an additional five papers, reporting on two studies (of which one was already identified in the electronic database search), which we also assessed in full text. We identified no new studies in the current update search. In total, we assessed the full text of 13 papers reporting on seven studies. </p> <div class="figure" id="CD008011-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD008011-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>Based on full‐text assessment, we finally included in this review seven papers reporting on two studies. We excluded six papers reporting on five studies. We have listed reasons for exclusion in the <a href="./references#CD008011-sec-0104" title="">Characteristics of excluded studies</a> table. </p> <p>By scanning the conference proceedings of relevant conferences, we identified two papers that have not yet been published in full text and are awaiting further assessment (see the <a href="./references#CD008011-sec-0105" title="">Characteristics of studies awaiting classification</a> table). By scanning the ongoing trials databases, we identified one additional ongoing trial (see the <a href="./references#CD008011-sec-0106" title="">Characteristics of ongoing studies</a> table). We identified no additional studies in the current update search of conference proceedings and trials databases. </p> </section> <section id="CD008011-sec-0066"> <h4 class="title">Included studies</h4> <p>We included two RCTs with a total of 203 participants in the review (<a href="./references#CD008011-bbs2-0001" title="ChenC , ZhouXZ , FanYM , QinLJ , GuoHX , XueHM , et al. Clinical analysis of Sodium phosphocreatine on cardiac toxicity induced by anthracycline antibiotics in acute leukemia children [Unknown original title in Chinese]. Chinese Journal of Cancer Prevention and Treatment2008;15(19):1503‐5, 510. ">Chen 2008</a>; <a href="./references#CD008011-bbs2-0002" title="GreevyR , LuB , SilberJH , RosenbaumPR . Optimal multivariate matching before randomization. Biostatistics2004;5(2):263‐75. GreevyR , SilberJH , CnaanA , RosenbaumPR . Randomization inference with imperfect compliance in the ACE‐inhibitor after anthracycline randomized trial. Journal of the American Statistical Association2004;99(465):7‐15. SilberJH . Challenges in conducting a pediatric longitudinal prevention study: lessons from the ACE‐inhibitor after anthracycline trial. Progress in Pediatric Cardiology2005;20:65‐70. SilberJH . The role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatric Blood &amp; Cancer2005;44:607‐13. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAHJ , RychikJ , et al. Design and baseline characteristics for the ACE inhibitor after anthracycline (AAA) study of cardiac dysfunction in long‐term pediatric cancer survivors. American Heart Journal2001;142:577‐85. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAJ , RychikJ , et al. Enalapril to prevent cardiac function decline in long‐term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology2004;22(5):820‐8. ">Silber 2004</a>); we identified no new studies in the current update. Six papers provided information on one trial (see all references under <a href="./references#CD008011-bbs2-0002" title="GreevyR , LuB , SilberJH , RosenbaumPR . Optimal multivariate matching before randomization. Biostatistics2004;5(2):263‐75. GreevyR , SilberJH , CnaanA , RosenbaumPR . Randomization inference with imperfect compliance in the ACE‐inhibitor after anthracycline randomized trial. Journal of the American Statistical Association2004;99(465):7‐15. SilberJH . Challenges in conducting a pediatric longitudinal prevention study: lessons from the ACE‐inhibitor after anthracycline trial. Progress in Pediatric Cardiology2005;20:65‐70. SilberJH . The role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatric Blood &amp; Cancer2005;44:607‐13. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAHJ , RychikJ , et al. Design and baseline characteristics for the ACE inhibitor after anthracycline (AAA) study of cardiac dysfunction in long‐term pediatric cancer survivors. American Heart Journal2001;142:577‐85. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAJ , RychikJ , et al. Enalapril to prevent cardiac function decline in long‐term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology2004;22(5):820‐8. ">Silber 2004</a>). We extracted information about the study from all six papers. </p> <p>In one trial, 69 participants received enalapril and 66 participants received placebo (<a href="./references#CD008011-bbs2-0002" title="GreevyR , LuB , SilberJH , RosenbaumPR . Optimal multivariate matching before randomization. Biostatistics2004;5(2):263‐75. GreevyR , SilberJH , CnaanA , RosenbaumPR . Randomization inference with imperfect compliance in the ACE‐inhibitor after anthracycline randomized trial. Journal of the American Statistical Association2004;99(465):7‐15. SilberJH . Challenges in conducting a pediatric longitudinal prevention study: lessons from the ACE‐inhibitor after anthracycline trial. Progress in Pediatric Cardiology2005;20:65‐70. SilberJH . The role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatric Blood &amp; Cancer2005;44:607‐13. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAHJ , RychikJ , et al. Design and baseline characteristics for the ACE inhibitor after anthracycline (AAA) study of cardiac dysfunction in long‐term pediatric cancer survivors. American Heart Journal2001;142:577‐85. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAJ , RychikJ , et al. Enalapril to prevent cardiac function decline in long‐term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology2004;22(5):820‐8. ">Silber 2004</a>). Participants were childhood cancer survivors with asymptomatic decline of cardiac function at some time during follow‐up after anthracycline exposure. Follow‐up time was a median of 2.80 (range 2 weeks to 6.1 years). </p> <p>In the other trial, 35 participants received phosphocreatine and 33 participants received a control treatment with vitamin C, adenosine triphosphate (ATP), vitamin E, and oral coenzyme Q10 (<a href="./references#CD008011-bbs2-0001" title="ChenC , ZhouXZ , FanYM , QinLJ , GuoHX , XueHM , et al. Clinical analysis of Sodium phosphocreatine on cardiac toxicity induced by anthracycline antibiotics in acute leukemia children [Unknown original title in Chinese]. Chinese Journal of Cancer Prevention and Treatment2008;15(19):1503‐5, 510. ">Chen 2008</a>). Participants were children with acute leukaemia and anthracycline‐induced cardiotoxicity, part of which was symptomatic. The duration of treatment was 14 days, and assessment of cardiac function was performed one day after the end of treatment; it is unclear if there was longer follow‐up, for example for the clinical outcomes. </p> <p>For more information see the <a href="./references#CD008011-sec-0103" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD008011-sec-0067"> <h4 class="title">Excluded studies</h4> <p>The number of excluded papers based on full‐text evaluation was six in total, reporting on five studies. A summary of the excluded studies can be found in the <a href="./references#CD008011-sec-0104" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD008011-sec-0068"> <h3 class="title">Risk of bias in included studies</h3> <p>We have summarised the evaluation of the risk of bias in the included studies below. An additional overview of evaluation in each domain per included study is provided in the <a href="./references#CD008011-sec-0103" title="">Characteristics of included studies</a> table ('Risk of bias' section) and summarised in <a href="#CD008011-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD008011-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008011-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD008011-sec-0069"> <h4 class="title">Allocation</h4> <p>In the enalapril study, allocation to treatment or control group was at random. For the allocation sequence, random permuted blocks with equal allocation were used within each stratum of prespecified variables (<a href="./references#CD008011-bbs2-0002" title="GreevyR , LuB , SilberJH , RosenbaumPR . Optimal multivariate matching before randomization. Biostatistics2004;5(2):263‐75. GreevyR , SilberJH , CnaanA , RosenbaumPR . Randomization inference with imperfect compliance in the ACE‐inhibitor after anthracycline randomized trial. Journal of the American Statistical Association2004;99(465):7‐15. SilberJH . Challenges in conducting a pediatric longitudinal prevention study: lessons from the ACE‐inhibitor after anthracycline trial. Progress in Pediatric Cardiology2005;20:65‐70. SilberJH . The role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatric Blood &amp; Cancer2005;44:607‐13. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAHJ , RychikJ , et al. Design and baseline characteristics for the ACE inhibitor after anthracycline (AAA) study of cardiac dysfunction in long‐term pediatric cancer survivors. American Heart Journal2001;142:577‐85. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAJ , RychikJ , et al. Enalapril to prevent cardiac function decline in long‐term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology2004;22(5):820‐8. ">Silber 2004</a>). Allocation was described as concealed, but the method of allocation concealment was not stated and was therefore unclear. </p> <p>In the phosphocreatine study, allocation to treatment or control group was also at random, but the method used to generate the allocation sequence was not described (<a href="./references#CD008011-bbs2-0001" title="ChenC , ZhouXZ , FanYM , QinLJ , GuoHX , XueHM , et al. Clinical analysis of Sodium phosphocreatine on cardiac toxicity induced by anthracycline antibiotics in acute leukemia children [Unknown original title in Chinese]. Chinese Journal of Cancer Prevention and Treatment2008;15(19):1503‐5, 510. ">Chen 2008</a>). It was not stated if there was allocation concealment. </p> </section> <section id="CD008011-sec-0070"> <h4 class="title">Blinding</h4> <p>The enalapril trial was reported to be a double‐blind study (<a href="./references#CD008011-bbs2-0002" title="GreevyR , LuB , SilberJH , RosenbaumPR . Optimal multivariate matching before randomization. Biostatistics2004;5(2):263‐75. GreevyR , SilberJH , CnaanA , RosenbaumPR . Randomization inference with imperfect compliance in the ACE‐inhibitor after anthracycline randomized trial. Journal of the American Statistical Association2004;99(465):7‐15. SilberJH . Challenges in conducting a pediatric longitudinal prevention study: lessons from the ACE‐inhibitor after anthracycline trial. Progress in Pediatric Cardiology2005;20:65‐70. SilberJH . The role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatric Blood &amp; Cancer2005;44:607‐13. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAHJ , RychikJ , et al. Design and baseline characteristics for the ACE inhibitor after anthracycline (AAA) study of cardiac dysfunction in long‐term pediatric cancer survivors. American Heart Journal2001;142:577‐85. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAJ , RychikJ , et al. Enalapril to prevent cardiac function decline in long‐term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology2004;22(5):820‐8. ">Silber 2004</a>). Although how the blinding was done was not clearly described, one of the additional papers concerning the trial stated that participants truly did not know which of the two treatments they had received (<a href="./references#CD008011-bbs2-0002" title="GreevyR , LuB , SilberJH , RosenbaumPR . Optimal multivariate matching before randomization. Biostatistics2004;5(2):263‐75. GreevyR , SilberJH , CnaanA , RosenbaumPR . Randomization inference with imperfect compliance in the ACE‐inhibitor after anthracycline randomized trial. Journal of the American Statistical Association2004;99(465):7‐15. SilberJH . Challenges in conducting a pediatric longitudinal prevention study: lessons from the ACE‐inhibitor after anthracycline trial. Progress in Pediatric Cardiology2005;20:65‐70. SilberJH . The role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatric Blood &amp; Cancer2005;44:607‐13. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAHJ , RychikJ , et al. Design and baseline characteristics for the ACE inhibitor after anthracycline (AAA) study of cardiac dysfunction in long‐term pediatric cancer survivors. American Heart Journal2001;142:577‐85. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAJ , RychikJ , et al. Enalapril to prevent cardiac function decline in long‐term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology2004;22(5):820‐8. ">Silber 2004</a>), indicating that blinding of participants was effective. It was also clearly stated that investigators were blinded to the intervention. However, it was not specified if the blinding of investigators concerned personnel as well as outcome assessors, if it was applicable to all studied outcomes, or if it was effective. Based on the effectiveness of blinding of participants and the statement that participants and investigators were blinded, we judged that this probably was the case. We consulted a third party regarding this judgement, who agreed with it. </p> <p>In the phosphocreatine trial, blinding was not described and based on the different types of route of administration per treatment and control group, we judged that blinding of participants and personnel was very unlikely (<a href="./references#CD008011-bbs2-0001" title="ChenC , ZhouXZ , FanYM , QinLJ , GuoHX , XueHM , et al. Clinical analysis of Sodium phosphocreatine on cardiac toxicity induced by anthracycline antibiotics in acute leukemia children [Unknown original title in Chinese]. Chinese Journal of Cancer Prevention and Treatment2008;15(19):1503‐5, 510. ">Chen 2008</a>). It was not stated if the investigators or outcome assessors were blinded, and we therefore we judged it to be unclear. </p> </section> <section id="CD008011-sec-0071"> <h4 class="title">Incomplete outcome data</h4> <p>In the enalapril trial, follow‐up was complete for overall survival, mortality due to heart failure, and development of clinical heart failure (<a href="./references#CD008011-bbs2-0002" title="GreevyR , LuB , SilberJH , RosenbaumPR . Optimal multivariate matching before randomization. Biostatistics2004;5(2):263‐75. GreevyR , SilberJH , CnaanA , RosenbaumPR . Randomization inference with imperfect compliance in the ACE‐inhibitor after anthracycline randomized trial. Journal of the American Statistical Association2004;99(465):7‐15. SilberJH . Challenges in conducting a pediatric longitudinal prevention study: lessons from the ACE‐inhibitor after anthracycline trial. Progress in Pediatric Cardiology2005;20:65‐70. SilberJH . The role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatric Blood &amp; Cancer2005;44:607‐13. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAHJ , RychikJ , et al. Design and baseline characteristics for the ACE inhibitor after anthracycline (AAA) study of cardiac dysfunction in long‐term pediatric cancer survivors. American Heart Journal2001;142:577‐85. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAJ , RychikJ , et al. Enalapril to prevent cardiac function decline in long‐term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology2004;22(5):820‐8. ">Silber 2004</a>). Follow‐up was complete for change in cardiac function for the study outcomes maximal cardiac index (MCI) and left ventricular end‐systolic wall stress (LVESWS), which were both measured in at least one post‐baseline measurement in more than 80% of the participants. However, it should be noted that it was unclear if follow‐up was complete for these parameters at the end of follow‐up. For other measures of cardiac function (shortening fraction (SF) and stress‐velocity index (SVI)) and the other outcomes that were reported (occurrence of adverse events and change in quality of life), it was unclear if the follow‐up was complete. One of the additional papers concerning this trial stated that a considerable fraction of the study participants ended participation, but did not report exact numbers and timing of study dropouts (<a href="./references#CD008011-bbs2-0002" title="GreevyR , LuB , SilberJH , RosenbaumPR . Optimal multivariate matching before randomization. Biostatistics2004;5(2):263‐75. GreevyR , SilberJH , CnaanA , RosenbaumPR . Randomization inference with imperfect compliance in the ACE‐inhibitor after anthracycline randomized trial. Journal of the American Statistical Association2004;99(465):7‐15. SilberJH . Challenges in conducting a pediatric longitudinal prevention study: lessons from the ACE‐inhibitor after anthracycline trial. Progress in Pediatric Cardiology2005;20:65‐70. SilberJH . The role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatric Blood &amp; Cancer2005;44:607‐13. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAHJ , RychikJ , et al. Design and baseline characteristics for the ACE inhibitor after anthracycline (AAA) study of cardiac dysfunction in long‐term pediatric cancer survivors. American Heart Journal2001;142:577‐85. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAJ , RychikJ , et al. Enalapril to prevent cardiac function decline in long‐term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology2004;22(5):820‐8. ">Silber 2004</a>). It was clearly stated that intention‐to‐treat (ITT) analysis was performed for the trial's primary and secondary outcomes. An extra per‐protocol analysis was performed on LVESWS. For the other measures of cardiac function (SF and SVI) it was unclear if an ITT analysis was performed. For overall survival, mortality due to heart failure, development of clinical heart failure, change in quality of life, and occurrence of adverse events, ITT analysis was possible, since the treatment allocation was abstractable for the reported outcomes.   </p> <p>In the phosphocreatine trial, complete assessment was done for overall survival, mortality due to heart failure, and occurrence of adverse events (<a href="./references#CD008011-bbs2-0001" title="ChenC , ZhouXZ , FanYM , QinLJ , GuoHX , XueHM , et al. Clinical analysis of Sodium phosphocreatine on cardiac toxicity induced by anthracycline antibiotics in acute leukemia children [Unknown original title in Chinese]. Chinese Journal of Cancer Prevention and Treatment2008;15(19):1503‐5, 510. ">Chen 2008</a>). For change in cardiac function, two parameters (echocardiography and hyper‐sensitivity C‐reactive protein (hsCRP)) were reported in all participants, while the other parameters of change in cardiac function outcomes (electrocardiogram (ECG), creatine kinase (CK), creatine kinase MB (CK‐MB), lactate dehydrogenase (LDH1), and alpha hydroxybutyrate dehydrogenase (alphaHBDH)) were only assessed in some participants and therefore not reported in this review. For overall survival, mortality due to heart failure, two parameters of change in cardiac function (echocardiography and hsCRP), and the occurrence of adverse events, ITT analysis was possible, since the treatment allocation was abstractable for all reported outcomes. </p> </section> <section id="CD008011-sec-0072"> <h4 class="title">Selective reporting</h4> <p>There was no sign of selective reporting in the enalapril trial (<a href="./references#CD008011-bbs2-0002" title="GreevyR , LuB , SilberJH , RosenbaumPR . Optimal multivariate matching before randomization. Biostatistics2004;5(2):263‐75. GreevyR , SilberJH , CnaanA , RosenbaumPR . Randomization inference with imperfect compliance in the ACE‐inhibitor after anthracycline randomized trial. Journal of the American Statistical Association2004;99(465):7‐15. SilberJH . Challenges in conducting a pediatric longitudinal prevention study: lessons from the ACE‐inhibitor after anthracycline trial. Progress in Pediatric Cardiology2005;20:65‐70. SilberJH . The role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatric Blood &amp; Cancer2005;44:607‐13. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAHJ , RychikJ , et al. Design and baseline characteristics for the ACE inhibitor after anthracycline (AAA) study of cardiac dysfunction in long‐term pediatric cancer survivors. American Heart Journal2001;142:577‐85. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAJ , RychikJ , et al. Enalapril to prevent cardiac function decline in long‐term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology2004;22(5):820‐8. ">Silber 2004</a>). A protocol was published that presented the outcomes that were planned to be studied as well as the planned data analyses (<a href="./references#CD008011-bbs2-0002" title="GreevyR , LuB , SilberJH , RosenbaumPR . Optimal multivariate matching before randomization. Biostatistics2004;5(2):263‐75. GreevyR , SilberJH , CnaanA , RosenbaumPR . Randomization inference with imperfect compliance in the ACE‐inhibitor after anthracycline randomized trial. Journal of the American Statistical Association2004;99(465):7‐15. SilberJH . Challenges in conducting a pediatric longitudinal prevention study: lessons from the ACE‐inhibitor after anthracycline trial. Progress in Pediatric Cardiology2005;20:65‐70. SilberJH . The role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatric Blood &amp; Cancer2005;44:607‐13. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAHJ , RychikJ , et al. Design and baseline characteristics for the ACE inhibitor after anthracycline (AAA) study of cardiac dysfunction in long‐term pediatric cancer survivors. American Heart Journal2001;142:577‐85. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAJ , RychikJ , et al. Enalapril to prevent cardiac function decline in long‐term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology2004;22(5):820‐8. ">Silber 2004</a>). All outcomes were reported and the analyses done in the final report (<a href="./references#CD008011-bbs2-0002" title="GreevyR , LuB , SilberJH , RosenbaumPR . Optimal multivariate matching before randomization. Biostatistics2004;5(2):263‐75. GreevyR , SilberJH , CnaanA , RosenbaumPR . Randomization inference with imperfect compliance in the ACE‐inhibitor after anthracycline randomized trial. Journal of the American Statistical Association2004;99(465):7‐15. SilberJH . Challenges in conducting a pediatric longitudinal prevention study: lessons from the ACE‐inhibitor after anthracycline trial. Progress in Pediatric Cardiology2005;20:65‐70. SilberJH . The role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatric Blood &amp; Cancer2005;44:607‐13. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAHJ , RychikJ , et al. Design and baseline characteristics for the ACE inhibitor after anthracycline (AAA) study of cardiac dysfunction in long‐term pediatric cancer survivors. American Heart Journal2001;142:577‐85. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAJ , RychikJ , et al. Enalapril to prevent cardiac function decline in long‐term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology2004;22(5):820‐8. ">Silber 2004</a>). The authors clearly explained that they performed some additional analyses based on exploration of the data. </p> <p>In the phosphocreatine trial, there was no published protocol, and we therefore cannot exclude selective reporting bias in the study (<a href="./references#CD008011-bbs2-0001" title="ChenC , ZhouXZ , FanYM , QinLJ , GuoHX , XueHM , et al. Clinical analysis of Sodium phosphocreatine on cardiac toxicity induced by anthracycline antibiotics in acute leukemia children [Unknown original title in Chinese]. Chinese Journal of Cancer Prevention and Treatment2008;15(19):1503‐5, 510. ">Chen 2008</a>). </p> </section> <section id="CD008011-sec-0073"> <h4 class="title">Other potential sources of bias</h4> <p>In the enalapril trial, we were not aware of other potential issues that could put the study at a high risk of bias (<a href="./references#CD008011-bbs2-0002" title="GreevyR , LuB , SilberJH , RosenbaumPR . Optimal multivariate matching before randomization. Biostatistics2004;5(2):263‐75. GreevyR , SilberJH , CnaanA , RosenbaumPR . Randomization inference with imperfect compliance in the ACE‐inhibitor after anthracycline randomized trial. Journal of the American Statistical Association2004;99(465):7‐15. SilberJH . Challenges in conducting a pediatric longitudinal prevention study: lessons from the ACE‐inhibitor after anthracycline trial. Progress in Pediatric Cardiology2005;20:65‐70. SilberJH . The role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatric Blood &amp; Cancer2005;44:607‐13. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAHJ , RychikJ , et al. Design and baseline characteristics for the ACE inhibitor after anthracycline (AAA) study of cardiac dysfunction in long‐term pediatric cancer survivors. American Heart Journal2001;142:577‐85. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAJ , RychikJ , et al. Enalapril to prevent cardiac function decline in long‐term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology2004;22(5):820‐8. ">Silber 2004</a>). </p> <p>In the phosphocreatine study, we had concerns about the comparability of the study participants, especially with regard to potential confounders such as gender, age, cumulative anthracycline dose, type of anthracycline, other cardiotoxic treatment, number of symptomatic participants, and the provision of other treatments during the study (<a href="./references#CD008011-bbs2-0001" title="ChenC , ZhouXZ , FanYM , QinLJ , GuoHX , XueHM , et al. Clinical analysis of Sodium phosphocreatine on cardiac toxicity induced by anthracycline antibiotics in acute leukemia children [Unknown original title in Chinese]. Chinese Journal of Cancer Prevention and Treatment2008;15(19):1503‐5, 510. ">Chen 2008</a>). </p> </section> </section> <section id="CD008011-sec-0074"> <h3 class="title" id="CD008011-sec-0074">Effects of interventions</h3> <p>Both trials did not allow data extraction for all endpoints. See the <a href="./references#CD008011-sec-0103" title="">Characteristics of included studies</a> table for a more detailed description of the extractable endpoints of each study. </p> <section id="CD008011-sec-0075"> <h4 class="title">Overall survival and mortality due to heart failure</h4> <p>We could extract data on overall survival and mortality due to heart failure from both studies. </p> <p>In the enalapril trial, there were no deaths in both the intervention and the control group during the study (<a href="./references#CD008011-bbs2-0002" title="GreevyR , LuB , SilberJH , RosenbaumPR . Optimal multivariate matching before randomization. Biostatistics2004;5(2):263‐75. GreevyR , SilberJH , CnaanA , RosenbaumPR . Randomization inference with imperfect compliance in the ACE‐inhibitor after anthracycline randomized trial. Journal of the American Statistical Association2004;99(465):7‐15. SilberJH . Challenges in conducting a pediatric longitudinal prevention study: lessons from the ACE‐inhibitor after anthracycline trial. Progress in Pediatric Cardiology2005;20:65‐70. SilberJH . The role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatric Blood &amp; Cancer2005;44:607‐13. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAHJ , RychikJ , et al. Design and baseline characteristics for the ACE inhibitor after anthracycline (AAA) study of cardiac dysfunction in long‐term pediatric cancer survivors. American Heart Journal2001;142:577‐85. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAJ , RychikJ , et al. Enalapril to prevent cardiac function decline in long‐term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology2004;22(5):820‐8. ">Silber 2004</a>). However, one participant from the placebo group (1.5%) died eight months after the end of the study, as a result of congestive heart failure. As it was unclear if both the intervention group and placebo group had been followed beyond the end of the study, we did not calculate a risk ratio (RR) of death due to heart failure including this late death. </p> <p>In the phosphocreatine trial, there were no deaths in both the intervention and the control group during the study (<a href="./references#CD008011-bbs2-0001" title="ChenC , ZhouXZ , FanYM , QinLJ , GuoHX , XueHM , et al. Clinical analysis of Sodium phosphocreatine on cardiac toxicity induced by anthracycline antibiotics in acute leukemia children [Unknown original title in Chinese]. Chinese Journal of Cancer Prevention and Treatment2008;15(19):1503‐5, 510. ">Chen 2008</a>). </p> </section> <section id="CD008011-sec-0076"> <h4 class="title">Development of clinical heart failure (as defined by authors)</h4> <p>The enalapril trial provided data on the occurrence of clinical heart failure, which the authors predefined as a clinically significant decline in cardiac performance (<a href="./references#CD008011-bbs2-0002" title="GreevyR , LuB , SilberJH , RosenbaumPR . Optimal multivariate matching before randomization. Biostatistics2004;5(2):263‐75. GreevyR , SilberJH , CnaanA , RosenbaumPR . Randomization inference with imperfect compliance in the ACE‐inhibitor after anthracycline randomized trial. Journal of the American Statistical Association2004;99(465):7‐15. SilberJH . Challenges in conducting a pediatric longitudinal prevention study: lessons from the ACE‐inhibitor after anthracycline trial. Progress in Pediatric Cardiology2005;20:65‐70. SilberJH . The role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatric Blood &amp; Cancer2005;44:607‐13. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAHJ , RychikJ , et al. Design and baseline characteristics for the ACE inhibitor after anthracycline (AAA) study of cardiac dysfunction in long‐term pediatric cancer survivors. American Heart Journal2001;142:577‐85. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAJ , RychikJ , et al. Enalapril to prevent cardiac function decline in long‐term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology2004;22(5):820‐8. ">Silber 2004</a>). In the intervention group, one participant (1%) developed such a significant decline, while in the control group this occurred in six (9%) participants (RR 0.16, 95% confidence interval (CI) 0.02 to 1.29; P = 0.09). See also <a href="./references#CD008011-fig-0005" title="">Analysis 1.1</a> and <a href="#CD008011-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD008011-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Enalapril versus placebo, outcome: 1.1 Development of clinical heart failure." data-id="CD008011-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Enalapril versus placebo, outcome: 1.1 Development of clinical heart failure. </p> </div> </div> </div> </section> <section id="CD008011-sec-0077"> <h4 class="title">Occurrence of adverse events and tolerability (as defined by authors)</h4> <p>Both studies reported on the occurrence of adverse events. Neither study reported severity or grading. </p> <p>In the enalapril trial, all participants were evaluated on the occurrence of adverse events (<a href="./references#CD008011-bbs2-0002" title="GreevyR , LuB , SilberJH , RosenbaumPR . Optimal multivariate matching before randomization. Biostatistics2004;5(2):263‐75. GreevyR , SilberJH , CnaanA , RosenbaumPR . Randomization inference with imperfect compliance in the ACE‐inhibitor after anthracycline randomized trial. Journal of the American Statistical Association2004;99(465):7‐15. SilberJH . Challenges in conducting a pediatric longitudinal prevention study: lessons from the ACE‐inhibitor after anthracycline trial. Progress in Pediatric Cardiology2005;20:65‐70. SilberJH . The role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatric Blood &amp; Cancer2005;44:607‐13. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAHJ , RychikJ , et al. Design and baseline characteristics for the ACE inhibitor after anthracycline (AAA) study of cardiac dysfunction in long‐term pediatric cancer survivors. American Heart Journal2001;142:577‐85. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAJ , RychikJ , et al. Enalapril to prevent cardiac function decline in long‐term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology2004;22(5):820‐8. ">Silber 2004</a>). The number of adverse events in participants was presented per adverse event, and many events were recorded (see <a href="./references#CD008011-fig-0006" title="">Analysis 1.2</a> until <a href="./references#CD008011-fig-0017" title="">Analysis 1.13</a> for RRs and corresponding 95% CI, and <a href="#CD008011-tbl-0002">Table 2</a> for Fisher's exact P values in outcomes with no event in one of the two groups). A notable difference in adverse events between groups was the higher occurrence of dizziness or hypotension (RR 7.17, 95% CI 1.71 to 30.17; P = 0.007; <a href="./references#CD008011-fig-0006" title="">Analysis 1.2</a>; <a href="#CD008011-fig-0004">Figure 4</a>) and fatigue (Fisher's exact test, P = 0.013; <a href="#CD008011-tbl-0002">Table 2</a>) in the enalapril group. Other reported adverse events were not statistically different between groups (<a href="./references#CD008011-fig-0007" title="">Analysis 1.3</a> until <a href="./references#CD008011-fig-0017" title="">Analysis 1.13</a>, and <a href="#CD008011-tbl-0002">Table 2</a>). </p> <div class="figure" id="CD008011-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Enalapril versus placebo, outcome: 1.2 Dizziness or hypotension." data-id="CD008011-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Enalapril versus placebo, outcome: 1.2 Dizziness or hypotension.</p> </div> </div> </div> <div class="table" id="CD008011-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Fisher's exact test of outcomes with no events in the enalapril or placebo group</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Enalapril (n = 69)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Placebo (n = 66)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Dehydration</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Fatigue</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.013</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Fever</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Alopecia</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Severe sunburn</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Wolff‐Parkinson‐White syndrome</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Anorexia</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Cholecystitis or gallstones</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Elevated bilirubin</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Ulcerative colitis</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Diabetes</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Hypokalaemia</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Hyperthyroidism</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Second cancer</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Tumour recurrence</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Proteinuria</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Renal stones</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Epistaxis</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Impotence</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Taste disturbance</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> </tr> </tbody> </table> </div> <p>In the phosphocreatine trial, all participants were also evaluated for adverse events (<a href="./references#CD008011-bbs2-0001" title="ChenC , ZhouXZ , FanYM , QinLJ , GuoHX , XueHM , et al. Clinical analysis of Sodium phosphocreatine on cardiac toxicity induced by anthracycline antibiotics in acute leukemia children [Unknown original title in Chinese]. Chinese Journal of Cancer Prevention and Treatment2008;15(19):1503‐5, 510. ">Chen 2008</a>), however it was not stated what type of adverse events were assessed. No adverse events were found in participants of either the phosphocreatine group or the control group during the trial. </p> </section> <section id="CD008011-sec-0078"> <h4 class="title">Change in cardiac function measured by a diagnostic test</h4> <p>Both studies provided several measures of change in cardiac function in the treatment and control groups. </p> <p>The enalapril trial presented their results in unadjusted and adjusted linear mixed models of the change over time of MCI, LVESWS, SVI, and SF (<a href="./references#CD008011-bbs2-0002" title="GreevyR , LuB , SilberJH , RosenbaumPR . Optimal multivariate matching before randomization. Biostatistics2004;5(2):263‐75. GreevyR , SilberJH , CnaanA , RosenbaumPR . Randomization inference with imperfect compliance in the ACE‐inhibitor after anthracycline randomized trial. Journal of the American Statistical Association2004;99(465):7‐15. SilberJH . Challenges in conducting a pediatric longitudinal prevention study: lessons from the ACE‐inhibitor after anthracycline trial. Progress in Pediatric Cardiology2005;20:65‐70. SilberJH . The role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatric Blood &amp; Cancer2005;44:607‐13. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAHJ , RychikJ , et al. Design and baseline characteristics for the ACE inhibitor after anthracycline (AAA) study of cardiac dysfunction in long‐term pediatric cancer survivors. American Heart Journal2001;142:577‐85. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAJ , RychikJ , et al. Enalapril to prevent cardiac function decline in long‐term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology2004;22(5):820‐8. ">Silber 2004</a>). As the authors did not present dichotomous outcomes, we were unable to calculate RRs and therefore have described the outcomes as presented in the original study (reported as ITT analyses). All analyses were adjusted for anthracycline dose, age at diagnosis, follow‐up time, gender, and cardiac irradiation. No differences were detected in the rate of change of all outcome parameters between intervention and control groups (adjusted model coefficient and P value of effect of enalapril: MCI 0.17, P = 0.36; LVESWS ‐1.41, P = 0.24; SVI 0.004, P = 0.68; SF 0.07, P = 0.81). After the data became available, the study authors explored the data and subsequently performed a piecewise linear model on LVESWS. In this per‐protocol analysis (adjusted for the same covariates) they found that enalapril caused a decrease (that is improvement) in LVESWS (‐8.62 g/cm² change) compared with placebo (+1.66 g/cm² change) in the first year of treatment (P = 0.036). After the first year there was no statistically significant difference in LVESWS change between enalapril and placebo groups (‐0.30 versus +0.49 g/cm², P = 0.56). </p> <p>In the phosphocreatine trial, complete baseline and outcome parameters were provided for echocardiographic cardiac function and the cardiac marker hsCRP (<a href="./references#CD008011-bbs2-0001" title="ChenC , ZhouXZ , FanYM , QinLJ , GuoHX , XueHM , et al. Clinical analysis of Sodium phosphocreatine on cardiac toxicity induced by anthracycline antibiotics in acute leukemia children [Unknown original title in Chinese]. Chinese Journal of Cancer Prevention and Treatment2008;15(19):1503‐5, 510. ">Chen 2008</a>). All participants had normal echocardiograms before and at the end of treatment (not further specified). In the phosphocreatine group, mean (standard deviation (SD)) baseline levels of hsCRP were 8.79 (1.36) mg/L compared with 7.88 (2.08) mg/L in the control group, while post‐treatment levels were 2.23 (0.82) mg/L in the phosphocreatine group compared with 4.2 (1.52) mg/L in the control group. Since the SDs of the difference before and after treatment within each group were not provided, we could not estimate the mean difference. It is therefore unclear if the change in hsCRP was significantly different between treatment groups. For the cardiac enzymes CK, CK‐MB, LDH1, and alphaHBDH, only post treatment levels were provided and are therefore not presented in this review. For the outcomes ECG, troponin I and the combined outcome of all cardiac enzymes together (hsCRP, CK, CK‐MB, LDH1, alphaHBDH, troponin I), numbers of participants with normal or abnormal outcomes after the intervention were only provided for those participants with abnormal values at baseline. Since these outcomes were only assessed in a specific subgroup of the studied cohort, we did not present them in this review. </p> </section> <section id="CD008011-sec-0079"> <h4 class="title">(Duration of) hospitalisation for heart failure</h4> <p>None of the studies provided outcome data on the (duration of) hospitalisation for heart failure. </p> </section> <section id="CD008011-sec-0080"> <h4 class="title">Change in NYHA (New York Heart Association) stage for heart failure</h4> <p>None of the studies provided change in NYHA stage for heart failure as an outcome parameter. </p> <p>The phosphocreatine trial did provide change in symptoms after the intervention for the participants with symptoms at baseline (<a href="./references#CD008011-bbs2-0001" title="ChenC , ZhouXZ , FanYM , QinLJ , GuoHX , XueHM , et al. Clinical analysis of Sodium phosphocreatine on cardiac toxicity induced by anthracycline antibiotics in acute leukemia children [Unknown original title in Chinese]. Chinese Journal of Cancer Prevention and Treatment2008;15(19):1503‐5, 510. ">Chen 2008</a>). However, since this outcome was reported in less than 50% of the participants, we did not present these data in this review. </p> </section> <section id="CD008011-sec-0081"> <h4 class="title">Change in quality of life (as defined by authors)</h4> <p>The enalapril study provided some information on quality of life (<a href="./references#CD008011-bbs2-0002" title="GreevyR , LuB , SilberJH , RosenbaumPR . Optimal multivariate matching before randomization. Biostatistics2004;5(2):263‐75. GreevyR , SilberJH , CnaanA , RosenbaumPR . Randomization inference with imperfect compliance in the ACE‐inhibitor after anthracycline randomized trial. Journal of the American Statistical Association2004;99(465):7‐15. SilberJH . Challenges in conducting a pediatric longitudinal prevention study: lessons from the ACE‐inhibitor after anthracycline trial. Progress in Pediatric Cardiology2005;20:65‐70. SilberJH . The role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatric Blood &amp; Cancer2005;44:607‐13. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAHJ , RychikJ , et al. Design and baseline characteristics for the ACE inhibitor after anthracycline (AAA) study of cardiac dysfunction in long‐term pediatric cancer survivors. American Heart Journal2001;142:577‐85. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAJ , RychikJ , et al. Enalapril to prevent cardiac function decline in long‐term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology2004;22(5):820‐8. ">Silber 2004</a>). There were no differences between groups on any of the dimensions of the Short‐Form 36 General Health Survey or the Childhood Health Questionnaire‐85. No further information was provided. </p> </section> <section id="CD008011-sec-0082"> <h4 class="title">Costs as defined by authors</h4> <p>None of the included studies provided outcome data on costs.</p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008011-sec-0083" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008011-sec-0083"></div> <p>As a result of survival rates of childhood cancer patients now approximating 75%, there is a steadily growing group of young childhood cancer survivors who are faced with asymptomatic or even symptomatic anthracycline‐induced cardiac dysfunction. Many collaborative groups have advocated screening for cardiac dysfunction in childhood cancer patients and survivors (<a href="./references#CD008011-bbs2-0012" title="ArmenianSH , GelehrterSK , VaseT , VenkatramaniR , LandierW , WilsonKD , et al. Screening for cardiac dysfunction in anthracycline‐exposed childhood cancer survivors. Clinical Cancer Research2014;20(24):6314‐23. ">Armenian 2014</a>; <a href="./references#CD008011-bbs2-0013" title="ArmenianSH , HudsonMM , MulderRL , ChenMH , ConstineLS , DwyerM , et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. The Lancet Oncology2015;16(3):e123‐36. ">Armenian 2015</a>; <a href="./references#CD008011-bbs2-0017" title="Children's Oncology Group. Long‐term follow‐up guidelines for survivors of childhood, adolescent and young adult cancers, version 3.0. Arcadia, CA.2006. Available at: www.survivorshipguidelines.org. ">COG 2006</a>; <a href="./references#CD008011-bbs2-0049" title="SieswerdaE , PostmaA , vanDalenEC , van derPalHJ , TissingWJ , RammelooLA , et al. The Dutch Childhood Oncology Group guideline for follow‐up of asymptomatic cardiac dysfunction in childhood cancer survivors. Annals of Oncology2012;23(8):2191‐8. ">Sieswerda 2012</a>; <a href="./references#CD008011-bbs2-0050" title="Scottish Intercollegiate Guideline Network (SIGN). Long‐term follow up care of survivors of childhood cancer. 2013. SIGN publication no. 132: available at: http://www.sign.ac.uk/pdf/sign132.pdf. Accessed on 8 August 2016.. ">SIGN 2013</a>; <a href="./references#CD008011-bbs2-0051" title="SkinnerR , WallaceWH , LevittG . Therapy based long term follow up: A practice statement (second edition). United Kingdom Children's Cancer Study Group, Late Effects Group 2005. Available at: http://www.uhb.nhs.uk/Downloads/pdf/CancerPbTherapyBasedLongTermFollowUp.pdf. Accessed on 8 August 2016. ">Skinner 2005</a>). However, for appropriate screening for a disease, an effective treatment should be available (<a href="./references#CD008011-bbs2-0066" title="WilsonJMG , JungnerG . Principles and practice of screening for disease. WHO Chronicle1968;22(11):473. ">Wilson 1968</a>). In addition, physicians who are confronted with childhood cancer patients and survivors with cardiac dysfunction should be able to make a well‐informed decision regarding the risks and benefits of treatment options. Although ACE inhibitors and beta‐blockers improve subclinical and clinical outcomes in adult populations with symptomatic and asymptomatic cardiac dysfunction due to other causes (<a href="./references#CD008011-bbs2-0011" title="AbdullaJ , PogueJ , AbildstromSZ , KoberL , ChristensenE , PfefferMA , et al. Effect of angiotensin‐converting enzyme inhibition on functional class in patients with left ventricular systolic dysfunction ‐ a meta‐analysis. European Journal of Heart Failure2006;8(1):90‐6. ">Abdulla 2006</a>; <a href="./references#CD008011-bbs2-0016" title="The Cardiac Insufficiency Bisoprolol Study II (CIBIS‐II): a randomised trial. The Lancet1999;353(9146):9‐13. ">CIBIS‐II 1999</a>; <a href="./references#CD008011-bbs2-0021" title="FoodyJM , FarrellMH , KrumholzHM . Beta‐blocker therapy in heart failure: scientific review. JAMA2002;287(7):883‐9. ">Foody 2002</a>; <a href="./references#CD008011-bbs2-0023" title="GargR , YusufS . Overview of randomized trials of angiotensin‐converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA1995;273(18):1450‐6. ">Garg 1995</a>; <a href="./references#CD008011-bbs2-0029" title="JongP , YusufS , RousseauMF , AhnSA , BangdiwalaSI . Effect of enalapril on 12‐year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow‐up study. The Lancet2003;361(9372):1843‐8. ">Jong 2003</a>; <a href="./references#CD008011-bbs2-0044" title="PackerM , BristowMR , CohnJN , ColucciWS , FowlerMB , GilbertEM , et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. The New England Journal of Medicine1996;334(21):1349‐55. ">Packer 1996a</a>; <a href="./references#CD008011-bbs2-0045" title="PackerM , ColucciWS , Sackner‐BernsteinJD , LiangCS , GoldscherDA , FreemanI , et al. Double‐blind, placebo‐controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation1996;94(11):2793‐9. ">Packer 1996b</a>; <a href="./references#CD008011-bbs2-0052" title="Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. The New England Journal of Medicine1991;325(5):293‐302. ">SOLVD 1991</a>; <a href="./references#CD008011-bbs2-0064" title="WaagsteinF , BristowMR , SwedbergK , CameriniF , FowlerMB , SilverMA , et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. The Lancet1993;342(8885):1441‐6. ">Waagstein 1993</a>), the different aetiology makes it difficult to extrapolate these beneficial effects to childhood cancer patients and survivors with anthracycline‐induced cardiotoxicity. This is an update of the first systematic review, <a href="./references#CD008011-bbs2-0068" title="SieswerdaE , vanDalenEC , PostmaA , CheukDKL , CaronHN , KremerLCM . Medical interventions for treating anthracycline‐induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. Cochrane Database of Systematic Reviews2011, Issue 9. [DOI: 10.1002/14651858.CD008011.pub2] ">Sieswerda 2011</a>, summarising all evidence on medical interventions for anthracycline‐induced cardiotoxicity in childhood cancer patients and survivors. </p> <p>For a reliable evaluation of the effects of medical interventions for the treatment of anthracycline‐induced cardiotoxicity, the best study design is an RCT in which the only difference between the intervention and control group is the use of the medical intervention. However, because of the relative rareness of childhood cancer and therefore of survivors with cardiac dysfunction, we expected to find a low number of studies and therefore decided that both RCTs and CCTs were eligible for this review, keeping in mind the limitations of CCTs. </p> <p>We identified two eligible RCTs investigating different medical interventions in different study populations and with different lengths of follow‐up; in the update we identified no new studies. Since for both medical interventions only one study was available, we could make no definitive conclusions about their effects on anthracycline‐induced cardiotoxicity. One RCT on enalapril in childhood cancer survivors with asymptomatic anthracycline‐induced cardiotoxicity showed no significant effect of enalapril on overall survival, mortality due to heart failure, development of clinical heart failure, and quality of life compared with placebo (<a href="./references#CD008011-bbs2-0002" title="GreevyR , LuB , SilberJH , RosenbaumPR . Optimal multivariate matching before randomization. Biostatistics2004;5(2):263‐75. GreevyR , SilberJH , CnaanA , RosenbaumPR . Randomization inference with imperfect compliance in the ACE‐inhibitor after anthracycline randomized trial. Journal of the American Statistical Association2004;99(465):7‐15. SilberJH . Challenges in conducting a pediatric longitudinal prevention study: lessons from the ACE‐inhibitor after anthracycline trial. Progress in Pediatric Cardiology2005;20:65‐70. SilberJH . The role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatric Blood &amp; Cancer2005;44:607‐13. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAHJ , RychikJ , et al. Design and baseline characteristics for the ACE inhibitor after anthracycline (AAA) study of cardiac dysfunction in long‐term pediatric cancer survivors. American Heart Journal2001;142:577‐85. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAJ , RychikJ , et al. Enalapril to prevent cardiac function decline in long‐term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology2004;22(5):820‐8. ">Silber 2004</a>). Only a post‐hoc, per‐protocol analysis done by the study investigators themselves showed an improvement in a measure of cardiac function (LVESWS) in the enalapril group compared with the placebo group in the first year of treatment. No effect was found after one year for this or other echocardiographic parameters of cardiac function over time. Participants treated with enalapril had a higher risk of dizziness or hypotension and fatigue. We could make no conclusions about the effect of enalapril on (duration) of hospitalisation, change in NYHA stage of heart failure, and costs, since these outcomes were not studied. The other RCT, on phosphocreatine in children with acute leukaemia and symptomatic or asymptomatic anthracycline‐induced cardiotoxicity, showed no significant differences in overall survival, mortality due to heart failure, echocardiographic cardiac function, and adverse events compared with a control treatment with vitamin C, ATP, vitamin E, and oral coenzyme Q10 (in all outcomes no events/abnormalities in both groups) (<a href="./references#CD008011-bbs2-0001" title="ChenC , ZhouXZ , FanYM , QinLJ , GuoHX , XueHM , et al. Clinical analysis of Sodium phosphocreatine on cardiac toxicity induced by anthracycline antibiotics in acute leukemia children [Unknown original title in Chinese]. Chinese Journal of Cancer Prevention and Treatment2008;15(19):1503‐5, 510. ">Chen 2008</a>). The effect of the intervention on one marker (hsCRP) was unclear. The study did not report on development of clinical heart failure, (duration of) hospitalisation for heart failure, change in NYHA stage for heart failure, or costs. We could therefore draw no conclusions for these outcomes. </p> <p>It should be noted that the reasons for not finding significant beneficial effects in the enalapril trial could be due to the low number of participants (that is low power) and participant compliance and loss to follow‐up (<a href="./references#CD008011-bbs2-0002" title="GreevyR , LuB , SilberJH , RosenbaumPR . Optimal multivariate matching before randomization. Biostatistics2004;5(2):263‐75. GreevyR , SilberJH , CnaanA , RosenbaumPR . Randomization inference with imperfect compliance in the ACE‐inhibitor after anthracycline randomized trial. Journal of the American Statistical Association2004;99(465):7‐15. SilberJH . Challenges in conducting a pediatric longitudinal prevention study: lessons from the ACE‐inhibitor after anthracycline trial. Progress in Pediatric Cardiology2005;20:65‐70. SilberJH . The role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatric Blood &amp; Cancer2005;44:607‐13. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAHJ , RychikJ , et al. Design and baseline characteristics for the ACE inhibitor after anthracycline (AAA) study of cardiac dysfunction in long‐term pediatric cancer survivors. American Heart Journal2001;142:577‐85. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAJ , RychikJ , et al. Enalapril to prevent cardiac function decline in long‐term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology2004;22(5):820‐8. ">Silber 2004</a>). Also, the fact that there was a low threshold for patients to be classified as having anthracycline‐induced cardiotoxicity could have influenced the identified effects of treatment. Patients with minor and sometimes temporary abnormalities were included, in which large benefits of the intervention were unlikely. In the SOLVD trial on enalapril in adults with asymptomatic cardiac dysfunction due to other causes than anthracyclines (<a href="./references#CD008011-bbs2-0053" title="Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. The New England Journal of Medicine1992;327(10):685‐91. ">SOLVD 1992</a>), a clear benefit of enalapril was found on the occurrence of clinical heart failure. This trial had a much larger sample size (4228 participants) and used a more strict definition to classify patients as having cardiac dysfunction (that is a left ventricular ejection fraction (LVEF) of 35% or less). The enalapril trial had a relatively short length of follow‐up (median 2.80 years). It is therefore unknown if there is a beneficial effect of enalapril in the longer term. In comparison, a follow‐up study of the earlier mentioned SOLVD trial showed beneficial effects of enalapril treatment on mortality during a 12‐year follow‐up (<a href="./references#CD008011-bbs2-0029" title="JongP , YusufS , RousseauMF , AhnSA , BangdiwalaSI . Effect of enalapril on 12‐year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow‐up study. The Lancet2003;361(9372):1843‐8. ">Jong 2003</a>; <a href="./references#CD008011-bbs2-0053" title="Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. The New England Journal of Medicine1992;327(10):685‐91. ">SOLVD 1992</a>). In the phosphocreatine trial (<a href="./references#CD008011-bbs2-0001" title="ChenC , ZhouXZ , FanYM , QinLJ , GuoHX , XueHM , et al. Clinical analysis of Sodium phosphocreatine on cardiac toxicity induced by anthracycline antibiotics in acute leukemia children [Unknown original title in Chinese]. Chinese Journal of Cancer Prevention and Treatment2008;15(19):1503‐5, 510. ">Chen 2008</a>), reasons for not identifying significant effects of the intervention could also be the low power and the very short duration of treatment and presumably also maximum follow‐up (that is 14 days). Also, the most optimal dosage schedule of phosphocreatine is currently unknown. Suboptimal dosages of study treatment could have led to the finding of no differences between treatment groups. </p> <p>The enalapril study had a low/moderate risk of bias (<a href="./references#CD008011-bbs2-0002" title="GreevyR , LuB , SilberJH , RosenbaumPR . Optimal multivariate matching before randomization. Biostatistics2004;5(2):263‐75. GreevyR , SilberJH , CnaanA , RosenbaumPR . Randomization inference with imperfect compliance in the ACE‐inhibitor after anthracycline randomized trial. Journal of the American Statistical Association2004;99(465):7‐15. SilberJH . Challenges in conducting a pediatric longitudinal prevention study: lessons from the ACE‐inhibitor after anthracycline trial. Progress in Pediatric Cardiology2005;20:65‐70. SilberJH . The role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatric Blood &amp; Cancer2005;44:607‐13. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAHJ , RychikJ , et al. Design and baseline characteristics for the ACE inhibitor after anthracycline (AAA) study of cardiac dysfunction in long‐term pediatric cancer survivors. American Heart Journal2001;142:577‐85. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAJ , RychikJ , et al. Enalapril to prevent cardiac function decline in long‐term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology2004;22(5):820‐8. ">Silber 2004</a>). There was a low/moderate risk of selection bias, performance bias, and detection bias. For most outcomes there was a low risk of attrition bias, but for some outcomes (the post‐hoc analysis of LVESWS, other parameters of cardiac function (SF and SVI), change in quality of life, and risk of adverse events), ITT analysis was not possible or it was unclear if follow‐up was complete, leading to a possible risk of attrition bias for these other outcomes. There were no other risks of bias, nor unexpected outcomes or inconsistencies in the data. The phosphocreatine study had a high risk of bias (<a href="./references#CD008011-bbs2-0001" title="ChenC , ZhouXZ , FanYM , QinLJ , GuoHX , XueHM , et al. Clinical analysis of Sodium phosphocreatine on cardiac toxicity induced by anthracycline antibiotics in acute leukemia children [Unknown original title in Chinese]. Chinese Journal of Cancer Prevention and Treatment2008;15(19):1503‐5, 510. ">Chen 2008</a>). We concluded there was a high risk of selection bias, performance bias, and detection bias. There was no sign of attrition bias. There was a risk of reporting bias, and we had concerns about the comparability of the two groups. We found no unexpected outcomes or other inconsistencies in the data. </p> <p>The external validity of a study indicates how well the results of the study can be generalised to individual patients with anthracycline‐induced cardiotoxicity during and after treatment for childhood cancer. Although we did not systematically assess this in this review, we regarded the external validity of the enalapril trial as reasonable (<a href="./references#CD008011-bbs2-0002" title="GreevyR , LuB , SilberJH , RosenbaumPR . Optimal multivariate matching before randomization. Biostatistics2004;5(2):263‐75. GreevyR , SilberJH , CnaanA , RosenbaumPR . Randomization inference with imperfect compliance in the ACE‐inhibitor after anthracycline randomized trial. Journal of the American Statistical Association2004;99(465):7‐15. SilberJH . Challenges in conducting a pediatric longitudinal prevention study: lessons from the ACE‐inhibitor after anthracycline trial. Progress in Pediatric Cardiology2005;20:65‐70. SilberJH . The role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatric Blood &amp; Cancer2005;44:607‐13. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAHJ , RychikJ , et al. Design and baseline characteristics for the ACE inhibitor after anthracycline (AAA) study of cardiac dysfunction in long‐term pediatric cancer survivors. American Heart Journal2001;142:577‐85. SilberJH , CnaanA , ClarkBJ , ParidonSM , ChinAJ , RychikJ , et al. Enalapril to prevent cardiac function decline in long‐term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology2004;22(5):820‐8. ">Silber 2004</a>). Participant characteristics were well‐defined, and the study population seemed to be a representative sample of childhood cancer survivors who can present with asymptomatic cardiotoxicity during follow‐up. However, it should be noted that a large proportion of participants had been treated previously with cardiac radiotherapy. It is not unlikely that the pathophysiology, course, and response to treatment of cardiac dysfunction that is induced by both anthracyclines and radiotherapy is different from cardiac dysfunction caused by anthracyclines only. In addition, other study characteristics could have influenced the effects of treatment. An observational study in adults with anthracycline‐induced cardiotoxicity suggested that time between the end of anthracycline treatment and start of heart failure treatment (including at least enalapril) influenced the chance of response to ACE inhibitors, with a longer follow‐up time associated with a lower chance of a beneficial effect (<a href="./references#CD008011-bbs2-0015" title="CardinaleD , ColomboA , LamantiaG , ColomboN , CivelliM , DeGiacomiG , et al. Anthracycline‐induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. Journal of the American College of Cardiology2010;55(3):213‐20. ">Cardinale 2010</a>). Another issue regarding the generalisability of the enalapril trial is that the diagnostic tools to determine cardiotoxicity that were used in this study are not easily used in daily practice. Especially equipment and expertise to determine MCI, LVESWS, and SVI may not be widely available in the follow‐up settings of childhood cancer survivors. As previously mentioned, the duration of follow‐up precludes extrapolation to follow‐up longer than three years. Finally, clear outcome definitions were provided, making it easy to extrapolate the study outcomes to daily practice. The phosphocreatine trial was less well generalisable to daily practice (<a href="./references#CD008011-bbs2-0001" title="ChenC , ZhouXZ , FanYM , QinLJ , GuoHX , XueHM , et al. Clinical analysis of Sodium phosphocreatine on cardiac toxicity induced by anthracycline antibiotics in acute leukemia children [Unknown original title in Chinese]. Chinese Journal of Cancer Prevention and Treatment2008;15(19):1503‐5, 510. ">Chen 2008</a>). Not all participant characteristics were described, including age and gender of the control group, time since leukaemia diagnosis, and information on (previous) cardiotoxic cancer treatment. No clear definitions (that is cutoff values of abnormal diagnostic tests) of cardiotoxicity were provided. No participant had an abnormal echocardiogram, and since most research on anthracycline‐induced cardiotoxicity, as well as guidelines on detection of cardiotoxicity, include echocardiographic examination of childhood cancer patients and survivors, we feel that the study group is not very representative with regard to cardiotoxicity (<a href="./references#CD008011-bbs2-0017" title="Children's Oncology Group. Long‐term follow‐up guidelines for survivors of childhood, adolescent and young adult cancers, version 3.0. Arcadia, CA.2006. Available at: www.survivorshipguidelines.org. ">COG 2006</a>; <a href="./references#CD008011-bbs2-0050" title="Scottish Intercollegiate Guideline Network (SIGN). Long‐term follow up care of survivors of childhood cancer. 2013. SIGN publication no. 132: available at: http://www.sign.ac.uk/pdf/sign132.pdf. Accessed on 8 August 2016.. ">SIGN 2013</a>; <a href="./references#CD008011-bbs2-0051" title="SkinnerR , WallaceWH , LevittG . Therapy based long term follow up: A practice statement (second edition). United Kingdom Children's Cancer Study Group, Late Effects Group 2005. Available at: http://www.uhb.nhs.uk/Downloads/pdf/CancerPbTherapyBasedLongTermFollowUp.pdf. Accessed on 8 August 2016. ">Skinner 2005</a>; <a href="./references#CD008011-bbs2-0055" title="SteinherzLJ , GrahamT , HurwitzR , SondheimerHM , SchwartzRG , ShafferEM , et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the cardiology committee of the Children's Cancer Study Group. Pediatrics1992;89:942‐9. ">Steinherz 1992</a>; <a href="./references#CD008011-bbs2-0060" title="VanDalenEC , van denBrugM , CaronHN , KremerLC . Anthracycline‐induced cardiotoxicity: Comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials. European Journal of Cancer2006;42:3199‐205. ">Van Dalen 2006b</a>). In addition, phosphocreatine is an experimental therapy and not a registered agent at the European Medicines Agency (EMA) or US Food and Drug Administration (FDA). Both the intervention and the control treatments are not common practice in most countries. Treatment duration and outcome assessment of cardiac function in this trial were only two weeks, so we only know the immediate effects of the intervention studied and not any long‐term benefits or harms. Based on these arguments, we feel that the outcomes of the phosphocreatine trial can hardly be extrapolated to daily clinical practice and care for childhood cancer patients (<a href="./references#CD008011-bbs2-0001" title="ChenC , ZhouXZ , FanYM , QinLJ , GuoHX , XueHM , et al. Clinical analysis of Sodium phosphocreatine on cardiac toxicity induced by anthracycline antibiotics in acute leukemia children [Unknown original title in Chinese]. Chinese Journal of Cancer Prevention and Treatment2008;15(19):1503‐5, 510. ">Chen 2008</a>). </p> <p>There was no evidence available from RCTs or CCTs for other medical interventions for treating anthracycline‐induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer (for a complete list of evaluated interventions, see the search strategy in <a href="./appendices#CD008011-sec-0090">Appendix 1</a>; <a href="./appendices#CD008011-sec-0091">Appendix 2</a>; <a href="./appendices#CD008011-sec-0092">Appendix 3</a>). </p> <p>Please note that in this review RCTs and CCTs were only eligible for inclusion when the participants (previously) had a type of childhood cancer (defined as a diagnosis of cancer at age 18 years or younger). RCTs or CCTs including both children and adults were only eligible for inclusion in this review if the majority of participants were 18 years or younger at cancer diagnosis. It is possible that there are RCTs or CCTs in adults that evaluate the effects of medical interventions on anthracycline‐induced cardiotoxicity in cancer patients or survivors. We did not systematically search for trials in adults, but we noted that there was an RCT on enalapril for treating adults with evidence of cardiotoxicity (as indicated by elevated troponin I) after high‐dose chemotherapy (which contained anthracycline in most participants) (<a href="./references#CD008011-bbs2-0014" title="CardinaleD , ColomboA , SandriMT , LamantiaG , ColomboN , CivelliM , et al. Prevention of high‐dose chemotherapy‐induced cardiotoxicity in high‐risk patients by angiotensin‐converting enzyme inhibition. Circulation2006;114(23):2474‐81. ">Cardinale 2006</a>). This trial found that participants treated with enalapril were significantly less likely to experience decline of left ventricular ejection fraction by 10% compared with untreated participants during one‐year follow‐up. There is another ongoing RCT of ranolazine for treatment of diastolic dysfunction in adults who completed standard dose chemotherapy for Hodgkin lymphoma, breast cancer, or colorectal cancer (<a href="./references#CD008011-bbs2-0039" title="MinottiG . Pharmacology at work for cardio‐oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs. Journal of Pharmacology and Experimental Therapeutics2013;346(3):343‐9. ">Minotti 2013</a>). However, this RCT is only aimed at short‐term evaluation of cardiac function parameters and biomarkers and will unlikely inform the efficacy of ranolazine in long‐term, patient‐oriented outcomes such as mortality or cardiac events. There were also some non‐controlled observational studies on adults with anthracycline‐induced cardiotoxicity (<a href="./references#CD008011-bbs2-0015" title="CardinaleD , ColomboA , LamantiaG , ColomboN , CivelliM , DeGiacomiG , et al. Anthracycline‐induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. Journal of the American College of Cardiology2010;55(3):213‐20. ">Cardinale 2010</a>; <a href="./references#CD008011-bbs2-0027" title="JensenBV , NielsenSL , SkovsgaardT . Treatment with angiotensin‐converting‐enzyme inhibitor for epirubicin‐induced dilated cardiomyopathy. The Lancet1996;347(8997):297‐9. ">Jensen 1996</a>; <a href="./references#CD008011-bbs2-0028" title="JensenBV , SkovsgaardT , NielsenSL . Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long‐term observational study of outcome in 120 patients. Annals of Oncology2002;13(5):699‐709. ">Jensen 2002</a>; <a href="./references#CD008011-bbs2-0042" title="NooriA , LindenfeldJ , WolfelE , FergusonD , BristowMR , LowesBD . Beta‐blockade in adriamycin‐induced cardiomyopathy. Journal of Cardiac Failure2000;6(2):115‐9. ">Noori 2000</a>; <a href="./references#CD008011-bbs2-0006" title="TallajJA , FrancoV , RayburnBK , PinderskiL , BenzaRL , PamboukianS , et al. Response of doxorubicin‐induced cardiomyopathy to the current management strategy of heart failure. Journal of Heart and Lung Transplantation2005;24(12):2196‐201. ">Tallaj 2005</a>; <a href="./references#CD008011-bbs2-0057" title="ThakurA , WittelesRM . Cancer therapy‐induced left ventricular dysfunction: interventions and prognosis. Journal of Cardiac Failure2014;20(3):155‐8. ">Thakur 2014</a>; <a href="./references#CD008011-bbs2-0007" title="VatutinNT , KetingEV , KalinkinaNV , DunaevaOA , KardashevskaiaLI . Effect of propranolol in silent myocardial ischemia induced by anthracyclines [Vliianie propranolola na bezbolevuiu ishemiiu miokarda, vyzvannuiu antratsiklinami]. Likars'ka sprava2001;1:106‐9. ">Vatutin 2001</a>). One of these studies evaluated ACE inhibitor (with or without a beta‐blocker) treatment in all study participants (<a href="./references#CD008011-bbs2-0015" title="CardinaleD , ColomboA , LamantiaG , ColomboN , CivelliM , DeGiacomiG , et al. Anthracycline‐induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. Journal of the American College of Cardiology2010;55(3):213‐20. ">Cardinale 2010</a>). This study was a prospective cohort study with a mean follow‐up of 36 months in 201 adults with symptomatic and asymptomatic cardiac dysfunction after anthracycline therapy, who were all treated with at least an ACE inhibitor as soon as cardiac impairment was noted. The study showed a (prespecified) response of cardiac function in 42%, a partial response in 13%, and no response in 45% of the study group. Responders had fewer cardiac events, and the study found a relationship between the duration of cardiac dysfunction and the probability of response to the therapy. The authors did not report if side effects occurred. It was concluded that beneficial effects of modern heart failure treatment are expected when treatment is started early after the detection of anthracycline‐induced cardiotoxicity. It should be noted that it is not always appropriate to extrapolate adult cancer (survivor) studies to childhood cancer (survivor) studies. Other age ranges, pharmacokinetics, pharmacodynamics, as well as comorbidities and co‐treatments may influence the effect of interventions for cardiotoxicity as well as the generalisability of studies to the clinical care of childhood cancer patients and survivors. Similarly, RCTs in other childhood populations are also difficult to generalise to childhood cancer patients and survivors. For example, in an RCT of the beta‐blocker carvedilol in children with symptomatic heart failure (<a href="./references#CD008011-bbs2-0005" title="ShaddyRE , BoucekMM , HsuDT , BoucekRJ , CanterCE , MahonyL , et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA2007;298(10):1171‐9. ShaddyRE , CurtinEL , SowerB , TaniLY , BurrJ , LaSalleB , et al. The pediatric randomized carvedilol trial in children with heart failure: rationale and design. American Heart Journal2002;144(3):383‐9. ">Shaddy 2007</a>), almost 40% of the study population had symptomatic heart failure due to congenital heart disease, with often a very different anatomy of the heart. </p> <p>Even though RCTs provide the highest levels of evidence, observational studies can sometimes be useful when no, or few, RCTs or CCTs are available. A retrospective cohort study described clinical and echocardiographic follow‐up of 18 childhood cancer survivors with symptomatic and asymptomatic anthracycline‐induced cardiotoxicity from the start of enalapril treatment during a median follow‐up of 10 years (<a href="./references#CD008011-bbs2-0034" title="LipshultzSE , LipsitzSR , SallanSE , SimbreVC , ShaikhSL , MoneSM , et al. Long‐term enalapril therapy for left ventricular dysfunction in doxorubicin‐treated survivors of childhood cancer. Journal of Clinical Oncology2002;20(23):4517‐22. ">Lipshultz 2002</a>). There were no serious side effects during the long‐term enalapril treatment in the cohort. The authors found an initial improvement of cardiac function, but a deterioration of cardiac function and clinical parameters after six years of follow‐up. However, the study was small, had no control group, and is highly prone to selection, detection, and performance bias. Another retrospective study of childhood cancer survivors treated with anthracyclines compared a group of 34 growth hormone (GH)‐treated children to a group of 86 children not treated with GH therapy (<a href="./references#CD008011-bbs2-0036" title="LipshultzSE , VlachSA , LipsitzSR , SallanSE , SchwartzML , ColanSD . Cardiac changes associated with growth hormone therapy among children treated with anthracyclines. Pediatrics2005;115:1613‐22. ">Lipshultz 2005b</a>). Echocardiographic assessments performed during routine clinical follow‐up were re‐analysed by an investigator blinded for the intervention. From repeated measurements analyses adjusted for baseline characteristics and non‐random missingness of data, the authors' main conclusion was that GH therapy increased left ventricular wall thickness during but not after therapy. It should be noted that among other issues, the retrospective construction of the control group, several confounding factors that were not adjusted for (such as co‐treatment with cardiovascular medication), and missing outcome data for a large part of the two groups, put this study at high risk for selection and attrition bias. We can therefore draw no (careful) conclusions from these two observational studies. </p> <p>We are awaiting the results of the ongoing study (<a href="./references#CD008011-bbs2-0010" title="NCT00003070 . Afterload reduction therapy for late anthracycline cardiotoxicity: a Pediatric Oncology Group Cancer Control Study. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT00003070. Accessed on 29 September 2015. ">NCT00003070</a>), as well as more information from the two studies for which we could not obtain enough information for inclusion (see <a href="./references#CD008011-sec-0105" title="">Characteristics of studies awaiting classification</a> table). There was no new information about this ongoing study and two studies awaiting classification during the update of the review. </p> </section> </section> <div class="figures-list"> <div class="figure" id="CD008011-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/urn:x-wiley:14651858:media:CD008011:CD008011-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_t/tCD008011-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD008011-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/full#CD008011-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008011-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/urn:x-wiley:14651858:media:CD008011:CD008011-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_t/tCD008011-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008011-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/full#CD008011-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008011-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/urn:x-wiley:14651858:media:CD008011:CD008011-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_t/tCD008011-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Enalapril versus placebo, outcome: 1.1 Development of clinical heart failure." data-id="CD008011-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Enalapril versus placebo, outcome: 1.1 Development of clinical heart failure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/full#CD008011-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008011-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/urn:x-wiley:14651858:media:CD008011:CD008011-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_t/tCD008011-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Enalapril versus placebo, outcome: 1.2 Dizziness or hypotension." data-id="CD008011-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Enalapril versus placebo, outcome: 1.2 Dizziness or hypotension.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/full#CD008011-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008011-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/urn:x-wiley:14651858:media:CD008011:CD008011-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_t/tCD008011-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enalapril versus placebo, Outcome 1 Development of clinical heart failure." data-id="CD008011-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Enalapril versus placebo, Outcome 1 Development of clinical heart failure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/references#CD008011-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008011-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/urn:x-wiley:14651858:media:CD008011:CD008011-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_t/tCD008011-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enalapril versus placebo, Outcome 2 Dizziness or hypotension." data-id="CD008011-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Enalapril versus placebo, Outcome 2 Dizziness or hypotension.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/references#CD008011-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008011-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/urn:x-wiley:14651858:media:CD008011:CD008011-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_t/tCD008011-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enalapril versus placebo, Outcome 3 Rash or hives." data-id="CD008011-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Enalapril versus placebo, Outcome 3 Rash or hives.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/references#CD008011-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008011-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/urn:x-wiley:14651858:media:CD008011:CD008011-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_t/tCD008011-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enalapril versus placebo, Outcome 4 Heart palpitations." data-id="CD008011-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Enalapril versus placebo, Outcome 4 Heart palpitations.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/references#CD008011-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008011-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/urn:x-wiley:14651858:media:CD008011:CD008011-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_t/tCD008011-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enalapril versus placebo, Outcome 5 Anxiety or depression." data-id="CD008011-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Enalapril versus placebo, Outcome 5 Anxiety or depression.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/references#CD008011-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008011-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/urn:x-wiley:14651858:media:CD008011:CD008011-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_t/tCD008011-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enalapril versus placebo, Outcome 6 Headache." data-id="CD008011-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Enalapril versus placebo, Outcome 6 Headache.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/references#CD008011-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008011-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/urn:x-wiley:14651858:media:CD008011:CD008011-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_t/tCD008011-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enalapril versus placebo, Outcome 7 Gastrointestinal disturbance." data-id="CD008011-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Enalapril versus placebo, Outcome 7 Gastrointestinal disturbance.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/references#CD008011-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008011-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/urn:x-wiley:14651858:media:CD008011:CD008011-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_t/tCD008011-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enalapril versus placebo, Outcome 8 Hepatitis C." data-id="CD008011-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Enalapril versus placebo, Outcome 8 Hepatitis C.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/references#CD008011-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008011-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/urn:x-wiley:14651858:media:CD008011:CD008011-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_t/tCD008011-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enalapril versus placebo, Outcome 9 Neutropenia." data-id="CD008011-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Enalapril versus placebo, Outcome 9 Neutropenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/references#CD008011-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008011-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/urn:x-wiley:14651858:media:CD008011:CD008011-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_t/tCD008011-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enalapril versus placebo, Outcome 10 Musculoskeletal pain." data-id="CD008011-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Enalapril versus placebo, Outcome 10 Musculoskeletal pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/references#CD008011-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008011-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/urn:x-wiley:14651858:media:CD008011:CD008011-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_t/tCD008011-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enalapril versus placebo, Outcome 11 Dry cough." data-id="CD008011-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Enalapril versus placebo, Outcome 11 Dry cough.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/references#CD008011-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008011-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/urn:x-wiley:14651858:media:CD008011:CD008011-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_t/tCD008011-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enalapril versus placebo, Outcome 12 Shortness of breath." data-id="CD008011-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Enalapril versus placebo, Outcome 12 Shortness of breath.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/references#CD008011-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008011-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/urn:x-wiley:14651858:media:CD008011:CD008011-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_t/tCD008011-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Enalapril versus placebo, Outcome 13 Chest pain." data-id="CD008011-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Enalapril versus placebo, Outcome 13 Chest pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/references#CD008011-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/media/CDSR/CD008011/image_n/nCD008011-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD008011-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Criteria list for the assessment of risk of bias of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Item ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Description</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Implementation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b><i>Selection bias</i> </b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>a</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Was the allocation sequence adequately generated?</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate when a random (and therefore unpredictable) sequence was used to allocate the intervention to the participants </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>b</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Was allocation adequately concealed?</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate when the upcoming allocations of participants were masked from those involved in enrolment into the trial </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b><i>Performance bias</i> </b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>c</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Was knowledge of the allocated intervention by participants adequately prevented during the study?</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate when the participants were unaware of the intervention they received</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>d</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Was knowledge of the allocated intervention by personnel adequately prevented during the study?</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate when the personnel involved in the care of the participants were unaware of the intervention a participant received </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b><i>Detection bias (for each outcome separately)</i> </b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>e</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Was knowledge of the allocated intervention by the outcome assessor adequately prevented during the study?</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate when the outcome assessor was unaware of the intervention a participant received</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b><i>Attrition bias (for each outcome separately)</i> </b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>f</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Was the follow‐up of the outcome complete?</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complete when the outcome was assessed in at least 80% of the study cohort</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>g</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Was an intention‐to‐treat‐analysis performed?</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate when all participants were analysed in the treatment group to which they were randomised, regardless of whether or not they received the allocated intervention </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b><i>Reporting bias</i> </b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>h</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Are reports of the study free of the suggestion of selective outcome reporting?</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate when a study protocol was available that prespecified study outcomes and analyses, which were all reported in the final study report </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b><i>Other sources of bias</i> </b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>i</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Was the study apparently free of other problems that could put it at a high risk of bias?</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate when there were no other important personal concerns about bias not addressed in the other domains in the tool </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>All items were scored yes, no, or unclear.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Criteria list for the assessment of risk of bias of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/full#CD008011-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008011-tbl-0002"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Fisher's exact test of outcomes with no events in the enalapril or placebo group</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Enalapril (n = 69)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Placebo (n = 66)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Dehydration</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Fatigue</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.013</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Fever</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Alopecia</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Severe sunburn</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Wolff‐Parkinson‐White syndrome</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Anorexia</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Cholecystitis or gallstones</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Elevated bilirubin</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Ulcerative colitis</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Diabetes</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Hypokalaemia</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Hyperthyroidism</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Second cancer</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Tumour recurrence</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Proteinuria</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Renal stones</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Epistaxis</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Impotence</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Taste disturbance</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Fisher's exact test of outcomes with no events in the enalapril or placebo group</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/full#CD008011-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008011-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Enalapril versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Development of clinical heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.02, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Dizziness or hypotension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.17 [1.71, 30.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Rash or hives <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.25, 3.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Heart palpitations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.83 [0.44, 33.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Anxiety or depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [0.18, 20.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.83 [0.44, 33.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Gastrointestinal disturbance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.20, 4.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Hepatitis C <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.11, 3.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.04, 5.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Musculoskeletal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.20, 4.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Dry cough <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.06, 14.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Shortness of breath <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.14, 6.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Chest pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.51, 5.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Enalapril versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008011.pub3/references#CD008011-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008011.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008011-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008011-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="ja#CD008011-note-0004">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD008011-note-0003">한국어</a> </li> <li class="section-language"> <a class="" href="ru#CD008011-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008011-note-0011">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br/> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008011\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008011\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008011\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008011\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008011\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008011\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008011\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008011\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008011\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008011\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008011\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008011\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008011\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008011\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008011\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008011\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008011\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008011\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jxlIh5Me&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008011.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008011.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008011.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008011.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008011.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729690483"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008011.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729690487"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008011.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ee31039149377',t:'MTc0MDcyOTY5MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 